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ABSTRACT

ESSENTIAL RNA-RNA INTERACTIONS WITHIN THE HEPATITIS C VIRUS
GENOME AS POTENTIAL TARGETS FOR PEPTIDE NUCLEIC ACID BASED
THERAPEUTIC STRATEGY

By
Sumangala Shetty
May 2011

Dissertation supervised by Dr. Mihaela-Rita Mihailescu
Hepatitis C, a life threatening disease, caused by the hepatitis C virus (HCV)
currently affects over 170-200 million people worldwide (~3% of global human
population), more than five times the percentage of total HIV infections. HCV infection
has been shown to be a major cause of chronic hepatitis, liver cirrhosis, and
hepatocellular carcinoma and is the leading cause of liver transplantation in the U.S.
HCV has escaped every therapeutic target to date by means of its error-prone RNA
polymerase, which allows it to mutate prolifically. The current standard anti-HCV
therapy, which is pegylated interferon α combined with ribavirin, is difficult to tolerate,
and more than 50% of HCV patients are refractory to it. No protective vaccine or
therapeutic antibody is available, making the need for the development of an efficacious
immunoprophylactic and therapeutic agent imperative. HCV is an enveloped virus with a
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positive sense RNA genome of ~9.6 kilobases (kb), which carries a large open reading
frame (ORF), flanked by 5’- and 3’- untranslated regions (UTRs). Interestingly, within
the highly mutational HCV RNA, there are a limited number of 100% conserved and
functionally vital motifs, located in the 5’ UTR, coding region and in the 3’ UTR. Within
the HCV genome, these motifs have been proposed to be involved in multiple exclusive
interactions with each other and furthermore, these interactions have been demonstrated
to be essential for HCV replication and/or translation of the viral proteins.
In this study, we used biophysical methods to characterize at the molecular level
these proposed HCV RNA-RNA essential interactions involving the highly conserved
motifs. Our results indicate that all of these interactions are mediated via kissing complex
formation, which have nanomolar dissociation constants. The ability of these conserved
motifs to be engaged in multiple interactions suggests the existence of RNA molecular
switches, which might regulate the transition between viral replication, translation,
packaging and/or other essential processes within HCV life cycle. Given the highly
mutational character of HCV genome, analysis of the highly conserved motifs provides
valuable information, which aids in identification of new potential therapeutic targets.
Subsequently, we designed and analyzed the ability of peptide nucleic acids to function
as therapeutic agents by disrupting these essential interactions in HCV and thus,
inhibiting the viral replication/translation. Our results show unambiguously that a single
PNA molecule designed against a conserved motif located in the 3’UTR effectively
disrupts and inhibits all possible interactions involving that motif, thereby opening the
possibility of new therapeutic options against HCV replication.
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Chapter 1: INTRODUCTION

1.1 Hepatitis C virus: History and Background
In 1974, following the development of serological tests for infection by Hepatitis A
virus and Hepatitis B virus, the role of these viruses was evaluated in all transfusion
associated hepatitis (TAH). Surprisingly, approximately 90% of TAH were not accounted
for either by hepatitis A or hepatitis B virus and this new unknown cause of TAH
henceforth came to be termed as non-A non-B hepatitis (NANBH) (1,2,3,4). NANBH
was initially perceived as a mild disease. However, further studies concluded that
NANBH had a high propensity to cause chronic hepatitis, which then progressed to liver
cirrhosis and finally liver failure (1, 5, 6, and 7). Upon confirmation of serious liver
damage by NANBH, extensive effort and research was applied to identify the causative
agent. It was only in 1989, almost 2 decades later, by immunoscreening an expression
library derived from serum of a NANBH patient, that the causative agent of NANBH
was identified and termed as Hepatitis C virus (HCV) (1,8). However, visualization of the
virus was not yet possible, and in addition, biochemical characterization of viral products
became impossible due to low viral titers in serum and tissue (1,9,10). The un-culturable
in vitro status of HCV further lead to a very narrow view of the viral life cycle (1, 9).
Regardless of these impediments, great progress has been made over the last two decades
on HCV research (figure 1.A) (9, 11, 12, 13) using different in vivo and in vitro
expression systems (figure 1.B) (9, 11, 12, 13) and cell culture adaptive mutations.
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Figure 1. A. Progress in HCV research over last several decades B. Models used to study HCV

Comparative studies of different HCV strains revealed the HCV to be closely related
to genera Pestivirus and Flavivirus, members within the Flaviviridae family. However,
although the HCV showed similarity to Pestiviruses and Flaviviruses, the lack of
homology between the 3’-untranslated regions (length or sequence) of HCV and
Flaviviruses or Pestiviruses lead to HCV being placed in a separate genus called
Hepacivirus within the Flaviviridae family (figure 2) (1,14,15).
Family Flaviviridae

Genus: Flaviviruses
YFV - Yellow fever Virus
DENV – Dengue Virus
WNV – West Nile Virus
JEV – Japanese Encephalitis Virus

Genus: Hepaciviruses
HCV – Hepatitis C Virus
GBV –B – GB virus B
Genus: Pestiviruses
BVDV – Bovine Viral Diarrhea Virus
CSFV – Classical Swine Fever Virus

Figure 2: HCV Classification
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1.2 Hepatitis C virus
The Hepatitis C virus (HCV), a blood-borne hepatotrophic pathogen, has a current
infection estimate of over 200 million people worldwide (3% of human population)
(16,17). HCV transmission occurs commonly through blood transfusions, hemodialysis
and organ transplants, but sharing used needles, razor blades and sharing tattoo guns has
also contributed significantly to spreading of the virus (18).
A major cause of liver disease globally and the leading cause of liver transplantation
in North America, HCV chronic infections eventually progress into end stage liver
disease (19). In addition among the 50-80% of the HCV patients who show sustained
virologic response, there is a large population intolerant to the current standard therapy,
which consists of pegylated interferon-α and ribavirin (20,21). Currently, there is no
vaccine or successful therapeutic option available against HCV.

1.3 Hepatitis C virus: The viral particle
Based on electron microscopic examination and filtration studies, HCV particles have
been estimated to be spherical virions of 30-80 nm in size (22, 23, 24).

Black – Genomic RNA
Blue - Nucleocapsid
Orange – Lipid Envelope
Green – E1 & E2 Glycoproteins

Figure 3: Hepatitis C Virus particle (9).

Though the precise structure has yet to be elucidated, the current proposed structure
for the HCV particle is shown in figure 3 (9). In the center (shown in black) is the
3

genomic RNA (also known as plus (+) strand RNA or positive sense RNA), which is
surrounded by the nucleocapsid (shown in blue) which is composed of multiple copies of
the HCV core protein. Enveloping the nucleocapsid (shown in orange) is the host cell
derived lipid envelope, in which 2 glycoproteins E1 and E2 (shown in green), are
anchored.

1.4 Genomic organization
HCV genome (shown in black in figure 3) is a 9.6 kb positive strand RNA,
comprised of three regions (figure 4): a long open reading frame (ORF) in the center
flanked by highly structured and conserved untranslated regions (UTR) or non-coding
region at the 5’ and 3’-end, respectively.

5’-untranslated region (UTR)/
5’-Non-coding region

Open reading frame

Structural genes

3’-untranslated region (UTR)/
3’-Non-coding region

Non-Structural genes

Figure 4. Schematic diagram of the HCV RNA genome. In red is the open reading frame. In green is the
5’- untranslated region (UTR) or non-coding region. In purple is 3’- untranslated region (UTR) or noncoding region

Open Reading Frame (ORF): The ORF located in the center of the HCV RNA genome,
also known as coding region or translated region (figure 4 in red), encodes for a single
polyprotein of ~3000 amino acids, which is proteolytically cleaved into at least ten nonstructural and structural viral proteins (9,16) (Tables 1 and 2). The non-structural proteins
are NS2, NS3, NS4A, NS4B, NS5A and NS5B, while E1, E2, p7 and the capsid core
protein constitute the structural proteins (11, 25).
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Table 1: List of non-structural proteins coded by the HCV RNA (9, 18, 26 and references
therein)
Non-Structural

Characteristics

Proteins
NS2

Auto protease

NS3

Serine protease

NS4A

Cofactor to NS3

NS4B

Membranous web

NS5A

Manipulates host immune system

NS5B

Error prone RNA-dependent RNA polymerase

Table 2: List of structural proteins coded by the HCV RNA (9, 18, 26 and references
therein)
Structural Proteins

Characteristics

Core

Genome encapsidation

E1

Glycoproteins for viral entry

E2

Glycoproteins for viral entry

The non-structural protein NS5B is an error-prone RNA-dependent RNA polymerase,
which confers the virus a high mutation rate during replication (9, 11).
5’-untranslated region (UTR): Since the time that HCV was first identified, a large
number of structural and functional studies have been conducted on the 5’ UTR of the
HCV genome (27, 28, 29, 30, and 31). Over the last several years, the secondary structure
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model for the 5’UTR of HCV has been repeatedly revised and revalidated both by
computational software as well as by biochemical techniques such as physical probing of
the RNA structure and mutational analysis. The current proposed structure is as shown in
figure 5 in green (28, 31).
The highly structured and conserved 5’- UTR spans a region of 341 nucleotides
(nts) and contains a highly structured (secondary and tertiary) complex composed of four
domains designated I to IV. Domain I serves as a translational regulator, domain II –III
together participate in the formation of an internal ribosome entry site (IRES), and
domain IV contains the translation initiation codon AUG (32,33,34,35 and references
therein).
Of the four domains, domain III which is the longest, contains six subdomains
labeled IIIa to IIIf and is crucial in recruiting the eukaryotic ribosome for translation of
the viral proteins. What is unique about the 5’UTR is that it serves as an internal
ribosome entry site that allows cap independent translation of HCV RNA (32, 33, 34, 35
and references therein).
Conventionally, in eukaryotes, translation initiation has the following stages (34
and references therein):
i.

Eukaryotic initiation factors (eIFs) recognize the 5’-cap structure (m7GpppN) of
the mRNA to be translated. One of the eIFs called Eif4f positions the 40S
ribosomal subunit close to the 5’cap structure of the mRNA to be translated and a
43S initiation complex is formed, which is composed of several eIFs, GTP and
Met-tRNAi.
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Figure 5: Represents the full length HCV RNA. Shown in green is the 5’untranslated region, in red is the coding region (indicated by the parallel lines is the
long stretch of nucleotides that code for the viral proteins), purple is the 3’ untranslated region. The colored lines represent the interactions investigated in this
study. Mustard line stands for interaction between apical loop of IIId with the internal loop of 5BSL3.2. Brown line stands for interaction between Alt with the
internal loop of 5BSL3.2. Blue line stands for interaction between apical loop of 5BSL3.2 and X55. Black line stands for interaction between X55 of one HCV
RNA and X55 of another HCV RNA (58).

ii.

This 43S complex then slides along the mRNA to be translated in a 5’ to 3’
direction until it encounters the initiation codon AUG. Upon attachment of the
43S complex to the AUG codon, the anticodon of the initiator tRNA base pairs
with the AUG codon to form a 48S initiation complex.

iii.

Following the formation of the 48S complex the eIFs are displaced from the 40S
ribosomal subunit. The 60S ribosomal subunit combines with the 40S ribosomal
subunit at the start codon to form an 80S ribosome, which initiates translation by
positioning the initiator Met-tRNA at the peptidyl (P) site.

In contrast to the conventional eukaryotic translation machinery, the 341 nt 5’-UTR of
HCV serves as an internal ribosome entry site (IRES) that directs cap-independent
translation of the HCV RNA. As in prokaryotes, the HCV 5’UTR IRES (34 and
references therein) can form a binary complex with 40S ribosomal subunit even in the
absence of translation initiation factors (eIFs). Following this, eIF2 and eIF3 promote
formation of the 48S initition complex, which then proceeds once again in the absence of
any (eIFs), to assemble into the final 80S ribosome at the start codon located in the IV
domain of 5’UTR of HCV RNA.
It is possible that other unconventional cellular or viral factors could possibly interact
with the HCV 5’UTR to regulate translation (36).
Along with regulatory viral translation, the HCV 5’UTR has also been proposed to
contain upstream signals that serve as cis-acting regulatory elements for viral RNA
synthesis (37).
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3’-untranslated region (UTR): On the opposite end of the open reading frame is the 225
nt 3’-untranslated region (UTR) (figure 4 in purple and also figure 5 in purple) (38,39),
which has a tri-domain organization comprised of (i) a non-conserved 40 nt hypervariable (HV) region; (ii) a poly (U/UC) stretch of 20-200 nts and (iii) a 3’-terminal
conserved 98 nt sequence named X-RNA (40,41,42). Together these three regions (figure
5 in purple) in the 3’UTR form defined stem loop structures, some of which are
proposed, others are known to engage cellular or viral proteins (40,41,42).
i.

Hyper-variable region (HV) region. The variable region of the 3’-UTR of the
HCV genome begins following a translation stop codon UGA in the open reading
frame. This upstream highly variable region composed of 21-40 nts confers
substantial sequence diversity among different HCV genotypes. Though the
variable region sequence or structure is not known to be an important determinant
of replication, a minor role in promoting the efficiency of HCV RNA replication
has been proposed (39).

ii.

Poly (U/UC) tract. Subsequent to the variable region is the variable length
poly(U/UC) tract ranging from 20-200 nts in different HCV genotypes. Different
studies revealed the optimal length of this tract for HCV RNA replication to be
between 33- 62 nts. Also, besides the length, the poly U tract composition was
demonstrated to be essential in its function for HCV RNA replication (39, 43).

iii.

X RNA. The terminal region of the 3’UTR of HCV RNA is composed of a 98 nt
region known as X RNA. Six years after the discovery of the virus in 1995, the X
RNA region was identified (42). Out of the 98 nt sequence of X RNA, chemical
probing data and mutational analysis supports the prediction that the X RNA
9

region forms at its 3’-end a stem-loop structure composed of the terminal 46 nts
(SL1) (39,41,44). However, the structure adopted by the first 55 nt of X RNA
(named in this study X55 RNA), which are 100% conserved among HCV
genotypes, remains controversial. Since homologous sequences have not been
found in related viruses, in phylogenetically distinct viruses or in cellular mRNAs
(44), the high level of conservation of the unique X55 region may be due to the
need to maintain certain secondary RNA structures during various processes in
the viral life-cycle (45).
The 3’ X RNA region has been shown to be essential as a cis-acting regulatory
element for RNA replication and may facilitate viral protein translation directed by the
viral IRES (43, 46).
Figure 6 shows two of the various predicted alternate conformations for X RNA
(47): both conformations predict the formation of the SL1 stem-loop, however, the
predicted folding of the X55 region is different: two stem-loops (SL2 and SL3) are
present in one conformation (figure 6, left), whereas an extended single stem-loop
containing internal bulges is present in the second (figure 6, right) (47).
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SLII&III

SLII

SLI

SLI
SLIII

Figure 6. Alternate conformations of HCV X RNA region. Shown in red is the 16nt palindromic sequence
termed as dimer linkage sequence (DLS) discussed in rationale 1.6.1.

Having detailed the three constituting regions of the HCV RNA genome (5’UTR,
coding region and 3’UTR), figure 5 reveals the true complex diagram of the HCV RNA.

1.5 Hepatitis C virus life cycle
The genomic RNA of HCV is also named plus strand RNA or positive RNA. Most of
the HCV life cycle illustrated in fig 7, is a proposed model: following viral entry and
internalization of the genomic RNA into the hepatocyte, translation is initiated to produce
both structural and non-structural viral proteins (as shown in tables 1 and 2).
Upon synthesis of the viral proteins, the viral polymerase NS5B initiates HCV
replication, by using the genomic plus strand RNA as a template and synthesizing a
complementary strand of RNA (named negative RNA) (18,27).
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NS4B
NS5A
NS5B
(+) RNA

(-) RNA

(+) RNA
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Figure 7. Hepatitis C Virus life cycle. Upon entry the HCV virus releases the (+) RNA genome shown in
black into the hepatic cell which gets involved in translation. Following translation, the (+) RNA uses the
translated protein NS5B which is an error prone RNA dependent RNA polymerase to undergo replication
within the membranous web shown as orange spheres. Following replication the newly synthesized (+)
RNA gets involved either in translation, replication or packaged into new virions.

The viral protein NS4B induces the formation of a membranous web, which serves as
a scaffold for HCV replication complex. The newly synthesized negative strand RNA
enters the membranous web and is subsequently employed as a template to synthesize
multiple copies of positive stranded RNA. The ratio of positive strand RNA to negative
strand RNA in infected cells has been estimated to be 10:1 (44,48). This newly
synthesized positive strand RNA is then recruited for either translation, synthesis of
negative strand RNA or packaged into new virions. The viral polymerase NS5B used for
replication is highly error-prone, thereby leading to accelerated viral evolution (9,11).

1.6.1 Rationale for studying interactions involving X55 RNA within the HCV
genome
As mentioned earlier, the HCV structure of the first 55 nt of HCV X RNA (X55), a
region 100% conserved among the HCV genotypes, remains controversial. The X55
12

region contains a 16 nt palindromic sequence shown in red in figure 6 (nt 9531 – nt 9546
in the context of the entire HCV genome), which is suggested to be responsible for the in
vitro homo-dimerization of the HCV RNA in the presence of the HCV core protein (47,
49). This HCV 16 nt palindromic sequence was named the “dimer linkage sequence”
(DLS), in analogy to the HIV-1 case (47). The mechanism of HCV genomic homodimerization is unknown and its biological significance for the HCV life cycle has not
been yet established. The finding that the HCV genome dimerizes is surprising, as this
function is generally found in Retroviridae, where it allows two copies of the genomic
RNA to be encapsidated in the virion, for example HIV (50,51,52,53). In HIV, genomic
dimerization plays a crucial role as a molecular switch and is currently a target for
potential anti-HIV drugs. Belonging to the Flaviviridae family, the HCV virion is
believed to contain a single copy of the genomic RNA (47, 49). Thus, the role played by
genomic RNA dimerization in the HCV life cycle is likely to be different. In this study
we analyze the conserved HCV X55 region and characterize for the first time the
mechanism of HCV genomic RNA dimerization.

1.6.2 Rationale for studying interaction between the coding region and the
untranslated regions on either ends of the HCV genome
Phylogenetically conserved RNA secondary structures have been analyzed for
their potential functional roles in the HCV coding region, using the HCV replicon
system. Lately several groups have reported that such a phylogenetically conserved stemloop structure (see figure 5 in red area and also figure 8) named 5BSL3.2 (also known as
SL-V (ref), SL9061 (ref), or SL9266 (ref)), located in the coding region, functions as a
13

cis-acting regulatory element (CRE) (figure 5 in red area and figure 8) (54, 55, 56). A
CRE is a region of RNA that regulates the expression of genes located on the same
molecule of RNA. 5BSL3.2 is composed of two short base-paired helices, separated by 8nt internal bulge loop on the 3’side and capped with a 12-nt apical loop (figure 8). It has
been shown indirectly by compensatory mutations and enzyme cleavage experiments that
the apical loop of 5BSL3.2 (sequence nt 9281-9287 within the entire HCV genome) is
interacting putatively in the presence of a chaperoning protein, with sequence 9540-9546
in the X RNA of the 3’ UTR (see figure 5, interaction shown in blue) (43,57). Also,
interesting is that the 5BSL3.2 internal bulge loop sequence (sequence 9297 – 9301
within the entire HCV genome) is predicted by the Evans group to be involved in a long
range interaction with an unstructured sequence 200 nt upstream of 5BSL3.2 named as
Alt (see figure 5, interaction marked in brown) and this interaction has been shown to be
essential for replication (56). Simultaneously, the same 5BSL3.2 internal bulge loop
(sequence 9297 – 9301) is predicted by the Berzal-Herranz group to interact with the IIId
domain (figure 5 interaction shown in mustard) located in the 5’UTR of the HCV genome
and this interaction has been proposed to be essential for translation (58). The present
work analyzes the various predicted interactions of cis-element 5BSL3.2 and proposes a
possible model involving each of the interactions within the HCV life cycle. A
diagrammatic summary of the four interactions analyzed in this study is shown in figure
5.
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Figure 9. Stem loop structure of IIId

1.7 Specific Aims of the Research
Specific Aim 1: Characterization of the highly conserved HCV X RNA region, focusing
in particular on its first 55 nt (named in this study X55 RNA).

Specific Aim 2: Identification and molecular characterization of HCV RNA essential
interactions as potential therapeutic targets
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Specific Aim 3: Design and analysis of peptide nucleic acid (PNA)’s that inhibit HCV
translation and replication

1.8 Relevance of the Research
Being highly mutational, HCV has thus far escaped all existing therapeutic
strategies. However, the RNA-RNA interactions under investigation in this study involve
sequences that are completely conserved in different HCV genotypes. Therefore, the
characterization of the interactions in which these conserved sequences are engaged, will
not only provide valuable information with respect to their functional importance, but
also aid in developing potential therapeutic strategies against HCV. Also, the current
study aims at contributing to our understanding of the life cycle of HCV, which even
today is not well elucidated. In this study, we elucidate the mechanism of HCV genomic
dimerization, a property otherwise known to exist to date only in retroviruses. Also, we
provide primary evidence on the existence of more than one conformation for the
conserved X55 region, thus explaining the universal ambiguity obtained so far on
structural studies of X55. In addition, we show for the first time direct experimental
evidence with respect to the proposed kissing interactions existent between the coding
and non-coding region of the HCV genome. All these results, allow the description of a
possible molecular switch within the HCV life cycle that can be used as potential
therapeutic target for HCV.
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Chapter 2: MATERIALS AND METHODS

2.1 RNA samples
A series of RNA oligonucleotides (wild type X55 RNA (55 nt), wild type IIId RNA
(37 nt), and wild type Alt (31 nt), as well as the related mutated forms of X55 RNA used
in the fluorescence spectroscopy studies, X55_C31, X55_C31_U5 RNAs and mutated 16
nt DLS_C9 RNA, were transcribed as previously described (59, 60) from synthetic DNA
templates in vitro using the T7 RNA polymerase in vitro transcription reactions. The
RNAs were purified by 10% polyacrylamide, 8 M urea gel electrophoresis, recovered by
electrophoretic elution, and dialyzed against either 1 mM cacodylic acid pH 6.5 or 10
mM Tris pH 7.5. Unless otherwise specified, all RNA samples were annealed prior to use
by heating at 95°C for 5 minutes, followed by snap-cooling on ice. Table 3 describes the
sequences of all RNAs used in this study, as well as their position with respect to the
entire HCV genome.
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Table 3: A-List of wild type RNA constructs used in this study
Wild type
RNA

No of
nucleotides

X55
5BSL3.2
IIId
Alt

55
48
37
31

Position in the
full length
RNA genome
9509-9563
9263-9310
253-289
9106-9123

Numbering in the
short RNA
constructs
1-55
1-48
1-37
1-31

Mutation

-----------------------------

Table 3: B-List of modified RNA constructs used in this study
Modified RNA
constructs

No of
nucleotides

Numbering in
the short RNA
constructs

Mutation

55

Position in
the full
length RNA
genome
9509-9563

X55_G30_31AP

1-55

X55_C31
X55_G30_52AP

55
55

9509-9563
9509-9563

1-48
1-37

X55_G30_U5

55

9509-9563

1-31

X98_G30_31AP

98

9509-9606

1-98

DLS_C9
5BSL3.2_21AP

16
48

9531-9546
9263-9310

1-16
1-48

U30(9538)-G
A31(9539)-2AP
A31(9539)-C
U30(9538)-G
A52(9560)-2AP
inserted
A31(9539)-C
U5(9512)-inserted
U30(9538)-G
A31(9539)-2AP
A9(9539)-C
A21(9283)-2AP

2.2 HCV core peptide
The full-length 191 amino acid HCV core protein contains three basic domains
(38, 47, and 49). The first two basic domains, comprising amino acid residues 2 – 23 and
38 -74, were combined to form a 58 amino acid sequence core peptide, which was named
the “2BD core” peptide (38, 47, 49). The core 2BD peptide was chemically synthesized
and purified by the Peptide Synthesis Unit at the University of Pittsburgh, Center for
Biotechnology and Bioengineering. The peptide was reconstituted in 1 mM cacodylic
acid pH 6.5 at a final concentration of 618 µM. The sequence of the peptide is
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PRRGPRLGVRATRKTSERSQPRGRRQPIPKVRHQTGRRGSRPNWGPNDPRRRSR
NLGK.
2.3 Native gel electrophoresis
The RNA samples were diluted from stock solutions to 0.05-20 µM
concentrations, and following boiling and snap-cooling, they were incubated in the
presence of 0.2 -10 mM MgCl2 either at 22°C (temperature at which a kissing complex
conformation is maintained) or at 55°C (temperature which promotes the formation of the
duplex conformation) for 2.5 hours. The samples were electrophoresed on 10-15% native
gels in either TBE (Tris Borate EDTA) buffer or TBM (Tris Borate Magnesium) buffer at
4ºC.
To study the effect of the 2BD core peptide on the magnesium treated X55 or IIId
5BSL3.2 samples, the peptide was directly added to the RNA, followed by incubation for
30 minutes at room temperature. These samples were subsequently treated with
proteinase K for peptide digestion (concentration of 190 µg/ml) for 1 h prior to being run
on native gels. The native gels were run at 4ºC, 40-100 V for 1.5 - 10 hours and were
visualized by UV shadowing at 254 nm using an AlphaImager HP (AlphaInnotech, Inc)
or by using SYBr Gold stain for gels containing nanomolar concentrations of RNA.

2.4 Fluorescence spectroscopy
Experiments were performed on a J.Y. Horiba Fluoromax-3 fluorimeter equipped with
variable temperature control. The excitation wavelength was set at 310 nm, and the
emission spectra were recorded from 330-450 nm. All experiments (i-iv) were performed
at 22°C.
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i.

X55 RNA kissing complex homodimer. All RNA constructs used in fluorescence

assay were numbered serially from 5’ to 3’ beginning with 1; however the true position in
reference to the full-length genome is given in parentheses. For the fluorescence
spectroscopy experiments, 2-aminopurine (2-AP), an adenine fluorophore analog, was
used to monitor the homodimerization of X55. The adenine of X55 at position 31
(nucleotide 9539 in the HCV full-length genome) as shown in figure 10A (top) circled in
red, was replaced with 2AP.
In the fluorescence spectroscopy assay, a fixed concentration of the labeled X55
was titrated with increments of unlabeled X55. However, since X55 homodimerizes in
the presence of magnesium, if used in the fluorescence spectroscopy assay, the wild type
X55 would lead to the formation of more than one species: unlabeled-unlabeled dimer,
labeled-labeled dimer, and labeled-unlabeled dimer (see figure 10 A,). Therefore, two
distinct RNAs were constructed for the fluorescence spectroscopy assay which analyzes
the dimerization of X55 RNA: (i) labeled X55_G30_31AP (figure 10B, left-middle)
which contained a point mutation shown in blue (U→G) at position 30 (nucleotide 9538
in full length genome), and in which the highly fluorescent purine analog 2-amino purine
(2AP) replaced the adenine circled in red at position 31 (nucleotide 9539 in full length
genome); and (ii) unlabeled X55_C31 (figure 10B, right-middle) which contained a point
mutation (A→C) shown in blue at position 31 (nucleotide 9539 in full length genome).
These point mutations prevented the homo-dimerization of the RNA constructs, but
allowed their hetero-dimerization thus giving a single species of labeled with unlabeled
(figure 10B, bottom).
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Figure 10. A. Shows the three different species of homodimers occurring if wild type 55nt XRNA is used
in the fluorescence spectroscopy assay. B. Shows the two new RNA constructs derived from the wild type
X 55 RNA (middle) and their heterodimer complex (bottom).

The dissociation constant of the kissing complex formed by X55 RNA, was
determined by titrating a fixed concentration of the fluorescent X55_G30_31AP (500
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nM) in 1 mM cacodylic acid pH 6.5 containing 10 mM MgCl2 with increasing
concentrations of X55_C31. The kissing complex dissociation constant was determined
by fitting the binding curve to equation 1:
F = 1+ (

( K + [ X 55 _ G30 _ 31AP]t + [ X 55 _ C31]t ) − ( Kd + [ X 55 _ G30 _ 31AP]t + [ X 55 _ C31]t )2 − 4 • [ X 55 _ G30 _ 31AP]t • [ X 55 _ C31]t
IB
− 1) • d
IF
2 • [ X 55 _ G30 _ 31AP]t

(1)

in which IB and IF are the steady state fluorescence intensities of the free and bound
X55_G30_31AP, [X55_G30_31AP] t is the total concentration of X55_G30_31AP RNA,
and [X55_C31] t is the total concentration of X55_C31 RNA (61,62).
Similarly, to analyze the interactions of the full length X RNA, X98_G30_31AP
was constructed (figure 11A left-middle), which contained a point mutation shown in
blue (U→G) at position 30 which corresponds to nucleotide 9538 in the full length
genome, and in which 2AP replaced the adenine at position 31 (nucleotide 9539 in full
length genome). This full length labeled X98_G30_31AP was titrated with the unlabeled
X55_C31.
For the analysis of the interactions between X55 and the isolated DLS region, the
X55_G30_31AP was titrated with the 16 nt DLS_C9, which contains a point mutation
(A→C) at position 9 (nucleotide 9539 in full length genome) (figure 11B, right-middle).
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Figure 11. A. RNA constructs used to determine the dissociation constant of the complex formed by the
98 nt X RNA and X55 RNA in the fluorescence spectroscopy assay. B. RNA constructs used to determine
the dissociation constant of the kissing complex formed by X55 RNA and the 16 nt DLS of X RNA in the
fluorescence spectroscopy assay.
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ii.

X55 RNA kissing complex to duplex conversion: To analyze the formation of the

X55 duplex conformation in the presence of the HCV core protein by fluorescence
spectroscopy, two additional RNAs were constructed: X55_G30_52AP (figure 12),
which retained the point mutation circled in blue (U→G) at position 30 (nucleotide 9538
in the full-length genome) to prevent homodimerization, but unlike the earlier sample in
which the 2AP was inserted in the terminal loop at position 31 (nucleotide 9539 in the
full-length genome), in this case the 2AP was introduced in the stem region as a single
bulged nucleotide at position 52 (nucleotide 9560 in the full-length genome) (figure 12).
The second sample was the complementary RNA construct X55_C31_U5 (figure 12),
which retained the point mutation (A→C) at position 31 circled in blue (nucleotide 9539
in the full-length genome) and had a uracil inserted at position 5 (nucleotide 9512 in full
length genome) (figure 12). These mutated constructs are not able to homodimerize due
to their mismatched terminal loops, but can heterodimerize. The structural isomerization
of X55 RNA was monitored by fluorescence spectroscopy by pre-forming the kissing
complex between X55_G30_52AP and X55_C31_U5 (100 nM each) in the presence of
10 mM MgCl2 and 140 mM KCl, and monitoring the decrease of the 2AP steady state
fluorescence upon the addition of an excess (500 nM) of the 2BD core peptide. All
conversion curves were corrected by subtracting the contribution of the peptide
background. The kissing complex to duplex conversion rate was determined using the
equation 2:
Ft = F1 ∗ exp(− kconv ∗ t ) + F2 ∗ exp(− k arr t ) + C
(2)
where kconv is the observed isomerization rate for conversion of the DLS kissing complex
to extended mature duplex dimer, and karr is attributed to the rate of rearrangement of the
2-AP probe subsequent to its stacking in the duplex conformation (61,62).
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Figure 12. RNA constructs X55_G30_52AP and X55_C31_U5 used to evaluate the conversion of the 55 nt
X RNA hetero kissing complex to a duplex in the fluorescence spectroscopy assay.

iii.

X55-5BSL3.2 RNA heterodimerization. The interactions of X55 RNA and

5BSL3.2 RNA were monitored by fluorescence spectroscopy by using a 2-AP labeled
5BSL3.2 RNA at position 21 (nucleotide 9283 in full length genome) (figure 13).
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Figure 13: Interacting base pairs between 5BSL3.2 and X55 are shown in red lines. Encircled in red on
5BSL3.2 is the adenine replaced with 2 –aminopurine for fluorescence assay. Note that the X55
conformation in this figure is different and is as proposed by the Bartenschlager group 2005 (57).
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The dissociation constant of the kissing complex formed by 5BSL3.2_21AP with
wild type X55 RNA, was determined by titrating a fixed concentration of the fluorescent
5BSL3.2_21AP (76 nM) in 1 mM cacodylic acid pH 6.5 containing 5 mM MgCl2 with
increasing concentrations of wild type X55. The kissing complex dissociation constant
was determined by fitting the binding curve to equation 3:
F = 1+ (

( K d + [ 5 BSL 3 .2 AP ]t + [ X 55 ]t ) −
IB
− 1) •
IF

( K d + [ 5 BSL 3 . 2 AP ]t + [ X 55 ]t ) 2 − 4 • [ 5 BSL 3 . 2 AP ]t • [ X 55 ]t
2 • [ 5 BSL 3 . 2 AP ]t

(3)

in which IB and IF are the steady state fluorescence intensities of the free and bound
5BSL3.2_21AP, [5BSL3.2_21AP] t is the total concentration of 5BSL3.2_21AP RNA and
[X55] t is the total concentration of X55 RNA.

iv. Effects of IIId or Alt RNAs on the X55-5BSL3.2 RNA heterodimerization. The
effects of IIId or Alt RNA on the X55-5BSL3.2 interactions, were evaluated by
fluorescence spectroscopy. 76 nM of 2-AP labeled 5BSL3.2 (5BSL3.2_2AP) was treated
with either IIId or Alt (1:1 ratio) in the presence of 5 mM MgCl2, after which, wild type
X55 was titrated into the mixture in nanomolar increments.
The dissociation constant of the kissing complex formed by 5BSL3.2_21AP and wild
type X55 RNA, was determined in the presence of equimolar ratio of either IIId or Alt
RNAs, by fitting the binding curves to equation 3:
F = 1+ (

( K d + [ 5 BSL 3 . 2 AP ]t + [ X 55 ]t ) −
IB
− 1) •
IF

( K d + [5 BSL 3 .2 AP ]t + [ X 55 ]t ) 2 − 4 • [5 BSL 3 .2 AP ]t • [ X 55 ]t
2 • [5 BSL 3 .2 AP ]t

(3)

in which IB and IF are the steady state fluorescence intensities of the free and bound
5BSL3.2_21AP, [5BSL3.2_21AP] t is the total concentration of 5BSL3.2_21AP RNA and
[X55] t is the total concentration of X55 RNA.

26

The 2AP labeled samples (55 nt X55_G30_31AP and X55_C31_52AP, 48nt
5BSL3.2_21AP and the full-length 98 nt X98_C31_31AP) were chemically synthesized
and purified by Dharmacon, Inc.

2.5 PNA experiments
PNA was obtained from our collaborator, Dr. Danith Ly of Carnegie Mellon
University. The PNA synthesized by the Ly group has a unique backbone modification at
the γ position wherein a serine side chain is inserted. This modified PNA is reported to
improve its hybridization properties by the Ly group. The PNA was prepared against the
sequence spanning from nt 9539 to nt 9548 of HCV (highlighted in purple in figure 14).
The PNA was diluted in 10 mM Tris buffer pH 7.5 and was used as provided from the Ly
lab without any pre-treatment (1.932 mM). The X55 RNA and 5BL3.2 RNA samples
were boiled and snap-cooled prior to being incubated with 5 mM MgCl2 for 10 minutes.
The PNA was incubated in a 2: 1 ratio with the X55 RNA and 5BL3.2 RNA samples to
confirm its specificity at 37°C. Upon confirmation of its specificity, the efficiency of
PNA was analyzed for different lengths of incubation time ranging from 0 to 4 hours, and
at different mixture ratios ranging from 0 – 8 fold of PNA: X55 RNA. Furthermore, the
dependence of PNA interactions with X55 RNA on temperature was also investigated.
The ability of the PNA to disrupt the interactions between X55 and 5BSL3.2 RNAs was
analyzed by 12% native gel electrophoresis, which were run at 4ºC, 40-100 V for 4 hours
and were visualized by UV shadowing at 254 nm using an AlphaImager HP
(AlphaInnotech, Inc).
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Figure 14: Left is one of the conformations of HCV X RNA (98nts). In red is the DLS region and
marked in purple is the target sequence against which the PNA was made. Right shows the target
X55 sequence base paired with the newly synthesized PNA sequence
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Chapter 3: RESULTS AND DISCUSSION- CHARACTERIZATION OF THE
HIGHLY CONSERVED HCV X RNA REGION

3.1 Investigation of X55 RNA dimerization
The HCV X RNA region has been shown to be involved in the in vitro RNA
homodimerization in the presence of the viral core protein (47), an interesting result
considering that the genomic RNA dimerization so far has been reported only in
retroviruses (50-53). The sequence responsible for the HCV RNA dimerization is a 16 nt
palindrome within X RNA (highlighted in red in figure 5), named DLS in analogy with
the DLS sequence of HIV-1, which is a 23 nt palindrome. In HIV-1, the genomic RNA
dimerization involves the formation of a kissing complex intermediate by the 23 nt DLS,
which is converted to an extended duplex by the nucleocapsid 7 protein (61,62,63). A
similar mechanism of RNA genomic dimerization was demonstrated for the murine
leukemia virus and it has been proposed to operate in other Retroviviridae members such
as avian leucosis sarcoma virus and mason-pfizer monkey virus (64).
We decided to investigate if this mechanism is more universal, being also
employed by HCV, which belongs to the Flaviviridae class. The HCV DLS region is 16
nt, however, since the structure adopted by the first 55 nt of X RNA (which include the
DLS region) is controversial, in this study we worked with the entire 55 nt region, which
will be named X55 RNA. Thus, we advanced the hypothesis that the HCV dimerization
involves the formation of a kissing complex intermediate by its DLS region, in the
absence of the core protein (figure 15, middle), which upon the action of the core protein
is converted to a more stable extended duplex conformation.
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Figure 15: Working hypothesis of X55 forming a kissing dimer in the presence of magnesium which
further gets converted to a duplex in the presence of HCV core 2BD.

Native gel electrophoresis studies. The formation of RNA kissing complexes requires
Mg2+ ions (65,66); thus, the first step in testing the above hypothesis was to determine if
X55 RNA dimerizes in the absence of the core protein in a MgCl2 dependent manner.

Figure 16: (Right) TBM native gel of X55 (20 µM) at different MgCl2 concentrations: 1 mM (lane 1),
5 mM (lane 2), and 10 mM (lane 3). Both the gel and the running buffer contained 1 mMMgCl2. (Left)
TBE native gel with no magnesium: Abnova RNA marker R0001 (lane 1) and wild-type X55 RNA
(lane 2).

As shown in figure 16 right, at MgCl2 concentrations ranging from 1 mM to 10
mM, there are two bands present on a native TBM gel of X55 RNA. However, the
monomer band which is most intense in the presence of 1 mM MgCl2 (lane 1) decreases
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in intensity with the concomitant increase in intensity of the dimer band at 5 mM MgCl2
(lane 2) and 10 mM MgCl2 (lane 3). While this result indicates that the X55 dimer
concentration increases with increasing MgCl2 concentrations, it does not prove
unambiguously the existence of an X55 kissing complex dimer, as both, the kissing
complex and the duplex conformations are dimeric (figure 15), and should migrate
similarly on a native TBM gel. However, the kissing complex conformation depends on
the presence of Mg2+ ions, thus, it will dissociate into monomers while migrating through
a TBE gel, where these ions are chelated by EDTA (65,66,67). However, once formed,
the duplex conformation will not be affected, as this conformation is not dependent on
the presence of Mg2+ ions. To distinguish the two X55 dimeric conformations (kissing
complex versus duplex), we ran two parallel gels, one in TBM which contained 10 mM
MgCl2 and one in TBE in which the Mg2+ ions are chelated (figure 17). X55 RNA was
snap-cooled and upon the addition of 10 mM MgCl2, two sets of samples were prepared:
the first set was incubated for 2.5 h at 22°C, (temperature at which the kissing complex
conformation is maintained), whereas the second set was incubated for 2.5 h at 55°C
(temperature which promotes the conversion of any kissing complex to the duplex
conformation).
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Figure 17: (Right) TBM gel containing 10 mM MgCl2. Both lanes contain X55 RNA annealed,
treated with 10 mM MgCl2 and incubated for 2.5 h at 55°C (lane 1) and 22°C (lane 2), respectively.
(Left) TBE native gel containing 2X EDTA. Both lanes contain X55 RNA annealed, treated with 10 mM
MgCl2 and incubated for 2.5 h at 55°C (lane 1) and 22°C (lane 2), respectively.

As seen in figure 17 right, in a TBM gel two bands, monomer and dimer (kissing
complex), are present in lane 2 which contains the X55 RNA sample incubated at 22°C;
whereas, as predicted, a single dimeric band (duplex) is present in the X55 RNA sample
incubated at 55°C (figure 17 right, lane 1). In contrast, in a TBE gel, in which the Mg2+
ions are chelated by EDTA, the dimer band of the X55 RNA incubated at 22°C is greatly
diminished with the concomitant increase of the monomer band intensity (figure 17 left,
lane 2), indicating the dissociation of the kissing complex. As expected, the dimer band
corresponding to the X55 RNA incubated at 55°C remains unchanged (figure 17 left, lane
1), since the duplex conformation is not affected by the absence of the Mg2+ ions. These
results strongly support the existence of a kissing complex dimer intermediate formed by
the X55 HCV RNA, in the absence of the core protein. Our results are in contrast to an
earlier report that the X-RNA region dimerization does not involve kissing dimer
intermediates formed in the absence of the HCV core protein (47). This difference is
likely due to the fact that micromolar RNA concentrations were used in our native gels,
as opposed to the picomolar concentrations used in previous studies (47). For a dimer
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complex with the dissociation constant in the nanomolar range (see below figure 18C),
the dimer species is negligible when the total RNA concentration used in the dimerization
assay is in the picomolar range.
Fluorescence spectroscopy studies. To obtain further support for the hypothesis
that a kissing complex intermediate is formed in the HCV RNA dimerization process, we
used a fluorescence spectroscopy assay initially developed to elucidate the HIV-1 RNA
dimerization (61,62). In this assay, the highly fluorescent purine analog 2-aminopurine
(2AP) replaces the adenine in the CUAG DLS hairpin loop at position 31 (nucleotide
9539 in the full-length genome), shown in red in figure 15, top. The 2-AP steady state
fluorescence is very sensitive to its microenvironment, being quenched by stacking
interactions (68). Thus, if a kissing complex is formed by X55 RNA in the presence of
MgCl2, the steady-state fluorescence of the 2AP reporter will be quenched due to the
change in its microenvironment from a single-stranded loop nucleotide (figure 15, top) to
a base paired stacked nucleotide in the kissing complex (figure 15, middle). To ensure
that a single 2AP reporter is present in the HCV X55 kissing complex, we designed an
X55 RNA construct in which the A at position 31 (nucleotide 9539 in the full-length
genome) in the CUAG DLS loop sequence was replaced by C as shown in green in figure
18A, and which was named X55_C31. To maintain the complementary base pairs in the
DLS loop, the 2AP containing X55 RNA had the U at position 30 (nucleotide 9538 in the
full-length genome) in the CUAG DLS loop replaced by G (shown in blue in figure 18A),
forming X55_G30_31AP. We proved by TBM native gel electrophoresis that neither
X55_G30_31AP, nor X55_C31 RNA is able to form homodimers due to their
mismatched loop sequences (figure 18B, lanes 1 and 2), whereas they form dimers when
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mixed in equimolar ratios (figure 18B, lane 3), like the wild type X55 RNA (figure 18B,
lane 4).
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Figure 18: (A) RNA samples used in the fluorescence spectroscopy assay to detect kissing
complex formation (the samples were 55 nt, but only the DLS region with the indicated
mutations highlighted in red, blue, and green is shown) [top] and their proposed kissing
interactions [bottom]. (B) TBM native gel showing that neither X55_G30_31AP RNA (lane 1)
nor X55_C31 RNA (lane 2) is able to homodimerize in the presence of 10 mM MgCl2, but
they heterodimerize when mixed (lane 3), similar to the wild-type X55 RNA (lane 4). (C) Plots of
the steady-state fluorescence of X55_G30_31AP (500 nM) in 1 mM cacodylic acid (pH 6.5) and 10
mM MgCl2, titrated with nanomolar increments of X55_C31 RNA (blue triangles), with a mutant
RNA X55_A30_A31, which contains a CAAG loop as opposed to the wild-type UAG loop (black squares),
or with a 21-nt fragment derived from EF1A mRNA (red circles). (D) Plot of the steady-state
fluorescence of the full-length X98_G30_31AP RNA (500 nM) in 1 mM cacodylic acid (pH 6.5) and
10 mM MgCl2, titrated with nanomolar increments of X55_C31. (E) Plot of the steady-state fluorescence
of X55_G30_31AP (500 nM) in 1 mM cacodylic acid (pH 6.5) and 10 mM MgCl2, titrated with
nanomolar increments of DLS_C9 RNA.
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The titration of the labeled X55_G30_31AP RNA (500 nM in 1 mM cacodylic
acid pH 6.5 and 10 mM MgCl2) with nanomolar increments of the complementary
unlabeled construct X55_C31 RNA resulted in a decrease in the fluorescence emission at
371 nm (figure 18C, blue triangles), due to the base stacking interactions arising when the
2AP in the labeled RNA (X55_G30_31AP) and the uracil in the unlabeled
complementary RNA construct (X55_C31) become involved in base pairs (figure 18A).
This interpretation is supported by the results of a control experiment which shows that
when a mutated X55 RNA with the sequence CAAG in the DLS loop (X55_A30_A31)
was titrated into X55_G30_31AP, the 2AP fluorescence of X55_G30_31AP did not
change significantly (figure 18C, black squares), as the non-complementarity of the DLS
loops of these two RNAs prevents the formation of their kissing complex. Similarly, no
significant decrease of the 2AP reporter was observed in a second control experiment in
which an unrelated single-stranded RNA derived from the EF1A mRNA was titrated into
X55_G30_31AP (figure 18C, red circles).
The binding curve of X55_C31 was fitted with equation 1 (materials and
methods) to determine the dissociation constant for the heterodimeric kissing complex
formed by X55_G30_31AP and X55_C31 as 318 ± 58 nM (figure 18C, blue triangles).
This value is in the same range as the dissociation constant of 200 nM determined for the
HIV-1 DLS kissing complex (69), and for other RNA kissing complexes (70, 71). It is
interesting to note that HCV, like other positive-strand viruses, forms membrane
associated replication complexes, known as “membranous webs”, which are composed of
vesicles 80 to 180 nm in diameter embedded in the membrane (72-74). Thus, it is
possible that the local concentration of the genomic RNA in the microenvironment
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created by the membranous webs in which RNA synthesis occurs reaches high enough
levels to allow the formation of a homodimeric kissing complex with a dissociation
constant in the nanomolar range.
To exclude any possibility of dimerization artifacts due to truncation of the 3’ part
of the genomic X RNA, we also analyzed the dimerization properties of the full-length 98
nt X RNA. Thus, we constructed a 98 nt X RNA which, like X55, had the A at position
31 (nucleotide 9539 in the full-length genome) replaced by 2AP and the U at position 30
(nucleotide 9538 in the full-length genome) replaced by G (indicated in figure 11A, leftmiddle), and analyzed its dimerization with X55_C31 RNA. By fitting the binding curve
of X98_G30_31AP with equation 1 (figure 18D), we determined a dissociation constant
of 323 ± 16 nM. The fact that the dissociation constants determined for X55_G30_31AP
and full-length X RNA X98_G30_31AP are the same within experimental error suggests
that the truncated X55 RNA mimics the behavior of the full-length X RNA and validates
our choice of X55 RNA as an useful model for the analysis of the X RNA
homodimerization process.
We also analyzed the dimerization properties of X55 RNA with the isolated 16
nt DLS sequence, which due to its size, is expected to fold as a simple stem-loop hairpin
(highlighted red sequence in figure 6). Thus, we constructed a 16 nt DLS (figure 11B,
right-middle) which had the A at position 9 (nucleotide 9539 in full length genome) in
the CUAG loop mutated for a C (DLS_C9), to maintain loop complementarity with
X55_G30_31AP. We determined the dissociation constant for the kissing complex
formed between X55_G30_31AP and the 16 nt DLS_C9 to be 188 ± 33 nM (figure 18E).
This value is in the same range as the dissociation constants determined for the
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X55_G30_31AP: X55_C31 and X98_G30_31AP: X55_C31 kissing complexes,
corresponding to a difference in free energy of kissing complex formation of only 0.3
kcal/mol. This result suggests that when participating in the formation of homodimeric
kissing complex interactions between two X RNA molecules, the DLS region adopts a
stem-loop conformation, as depicted in figure 6, right. However, it should be noted that
this finding does not rule out the existence of other alternate conformations of X55 RNA,
which would make possible its long-range interactions with the 5BSL3.2 hairpin, it just
infers that for the formation of a homodimeric kissing complex it is likely that the DLS
region is folded as a stem-loop.

3.2 The HCV core protein 2BD domain converts the X55 kissing complex
intermediate to a more stable duplex conformation
The HCV core protein is a 191 amino acid, highly basic, RNA binding protein
with a hydrophilic N terminus (containing three basic domains) and a hydrophobic C
terminus (38). Together with the viral glycoproteins, the core protein acts as a building
block of the viral nucleocapsid (18, 47, and 75). It has been also reported that the core
protein has nucleic acid chaperone properties (47); similar to those found in retroviral
nucleocapsid (NC) proteins (76-80). Since previously it has been shown that the fulllength HCV core protein and its isolated basic domains (either alone or in combination)
have similar nucleic acid chaperoning ability, in this study, we used a synthetic peptide
(2BD) representing a fusion of the first two basic domains of core, comprising residues 2
– 23 and 38 -74 (47).
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The second hypothesis we advanced in this study was that the kissing complex
intermediate formed by X55 RNA is converted to a more thermodynamically stable
extended duplex conformation by the core 2BD peptide (figure 15, bottom). To test this
hypothesis, we initially used native TBM gel electrophoresis: the core 2BD peptide was
directly added to the preformed wild type X55-X55 kissing complex and following
incubation for 0.5 h, proteinase K was added to the samples to degrade the 2BD core
peptide (47). As shown in figure 19A right side, after the action of the core 2BD peptide,
X55 RNA, which in the absence of the peptide exists as a mixture of monomer and dimer
(lane 1) has been converted to the dimer conformation (lane 3), which migrates at the
same position as the control X55 duplex obtained by incubating the X55 RNA in the
presence of 10 mM MgCl2 at 55°C for 2.5 h (lane 2) (47a). To determine if the X55
dimer conformation obtained after the action of the 2BD core peptide is indeed the
duplex conformation, we used TBE native gel electrophoresis. As seen in figure 19A left
side, in the presence of EDTA which chelates Mg2+ ions, X55 RNA incubated at 22°C
reverts to the monomeric state (lane 1), whereas neither the X55 sample treated by the
2BD core peptide (lane 2), nor the control duplex X55 RNA obtained by incubation at
55°C for 2.5 h (lane 3) are affected by EDTA. This result indicates that under the action
of the core 2BD peptide X55 RNA undergoes structural isomerization to the duplex
conformation.
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Figure 19: (A, right) TBM native gel: X55 RNA samples (20 µM) were annealed and treated with 10 mM
MgCl2, followed by incubation at 22°C (lane 1), incubation at 55°C (lane 2), and incubation at 22°C and
treatment with 1:2 RNA: core 2BD peptide (lane 3). (Left) TBE native gel: X55 RNA samples (20 µM)
were annealed and treated with 10 mM MgCl2, followed by incubation at 22°C (lane 1), incubation at
22°C, and treatment with 1:2 RNA: core 2BD peptide (lane 3) and incubation at 55°C (lane 2). (B) RNA
samples used in the fluorescence spectroscopy assay used to detect the kissing complex to duplex
structural isomerization. The inserted 2AP and uracil are highlighted in red, and the loop mutations are
highlighted in blue. (C) TBM native gel showing that neither X55_G30_52AP RNA (lane 1) nor
X55_C31_U5 RNA (lane 2) is able to homodimerize, but they heterodimerize when mixed in equimolar
ratio (lane 3), similar to the wild-type X55 RNA (lane 4). (D) Conversion of the kissing complex (100nM)
conformation to duplex by the 2BD core peptide (500nM) (black triangles). The curve was fit with
equation 2 (Materials and Methods) to determine the structural isomerization rate. Blue squares indicate
that the addition of the 2BD core peptide in the absence of MgCl2 does not quench the 2AP fluorescence.
Red circles indicate that no structural isomerization occurs in the absence of the core 2BD peptide.

To elucidate the mechanism of this structural isomerization we used a
fluorescence spectroscopy assay, similar to that previously employed for the study of the
HIV-1 dimer initiation site (61, 62). We constructed two additional X55 RNA molecules:
X55_G30_52AP, which retained the (U→G) at position 30 (nucleotide 9538 in the fulllength genome) as shown in blue in figure 19B, left and had a 2AP inserted in the lower
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stem region at position 52 (nucleotide 9560 in the full-length genome) shown in red in
figure 19B, left) to form a single nucleotide bulge; and X55_C31_U5, which retained the
point mutation (A→C) at position 31 (nucleotide 9539 in the full-length genome) as
shown in blue in figure 19B, right and had a uracil inserted in the lower stem at position 5
(nucleotide 9512 in the full-length genome) as shown in red in figure 19B, right. Due to
the G30 and C31 mutations these two X55 molecules have their DLS loops mismatched
and are not able to homodimerize, but can heterodimerize when mixed in equimolar ratio,
as shown on a native TBM gel (figure 19C). The steady state fluorescence of the 2AP in
X55_G30_52AP is expected to be high when this RNA is involved in a kissing complex
with X55_C31_U5 due to its internal bulge conformation (figure 19B, top). If the core
protein converts the kissing complex to the stable duplex conformation by a strand
exchange mechanism, the 2AP in X55_G30_52AP will base pair with the uracil at
position 9512 of X55_C31_U5, and since this newly formed 2AP-U base pair (shown in
red in figure 19B, bottom) will become part of the extended duplex, the steady state
fluorescence of the 2AP in X55_G30_52AP, is expected to be quenched over time due to
stacking interactions.
As shown in figure 19D, this is indeed the case, as an 80% decrease of the 2AP
steady state fluorescence is observed upon the addition of an excess of 2BD core peptide
to the preformed kissing complex between X55_G30_52AP and X55_C31_U5 in the
presence of 10 mM MgCl2 (black triangles). This result indicates that the 2BD core
peptide assists in the conversion of the kissing complex intermediate to the duplex
conformation by a strand-exchange mechanism, similarly to the mechanism reported for
the nucleocapsid 7 chaperoned structural isomerization of the HIV-1 RNA genome (61,
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62). To rule out the possibility that the observed quenching is due to the direct
interactions of the core 2BD peptide with the 2AP reporter and not the strand exchange
mechanism, we performed a control experiment in which the same excess of the core
2BD peptide was added to a mixture of X55_G30_52AP and X55_C31_U5, but in the
absence of MgCl2. As shown in figure 19D (blue squares), in this case, there is an initial
10% drop in the 2AP steady-state fluorescence, which over time returns to the 100%
intensity value, very different than the observed intensity drop due to the kissing complex
to duplex conformation conversion (black triangles). This result also indicates that the
kissing complex conformation formation is required for the core 2BD peptide activity, as
in the absence of Mg2+ ions, when the kissing complex does not form, the peptide cannot
convert X55_G30_52AP and X55_C31_U5 to the dimer conformation. This result was
also confirmed by native gel electrophoresis for the wild type X55 RNA, where it was
observed that no dimer band is present in the presence of an excess of the 2BD peptide,
but in the absence of Mg2+ ions (data not shown). Thus, it is likely that when assisting in
the structural isomerization of the HCV DLS, the core protein does not employ a “zipper”
pathway involving nucleation at the 3’-/5’-terminal ends, as the HIV-1 nucleocapsid
protein has been reported to use in the annealing of the full length transactivation
response element (TAR) (81). Also shown in figure 19D is the result of a second control
experiment (red circles), in which we confirmed that in the absence of the core 2BD
protein, the steady state fluorescence of X55_G30_52AP, which is involved in a kissing
complex with X55_C31_U5 in the presence of 10 mM MgCl2, remains almost constant
over time (5% drop in intensity), indicating that within the timeline of the experiment, the
conversion to the duplex conformation is minimal without the assistance of the 2BD core
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peptide. The rate of conversion from the kissing complex to the duplex conformation was
obtained by fitting the conversion curve (black triangles) with equation 2 (materials and
methods). The value of kconv = 1.7 ± 0.2 min-1 is very similar to that of kconv = 2.2 ± 0.2
min-1, reported for the conversion rate of the HIV-1 DIS kissing dimer to the mature
extended duplex by the nucleocapsid 7 protein (present in a 5:1 ratio, like in our
experiments).
Taken together, these results indicate that, like in the case of the HIV-1 DLS,
the mechanism of HCV RNA dimerization involves the formation of a kissing complex
intermediate, which in the presence of the core peptide undergoes isomerization through
the melting of intramolecular stem base-pairs and reformation of intermolecular base
pairing to form a more thermodynamically stable duplex conformation.

3.3 Conclusion: Possible biological role of the HCV genomic RNA dimerization
We have shown unambiguously that the mechanism of the genomic HCV
dimerization is very similar to that of the HIV-1, involving the formation of a kissing
complex intermediate which is converted to a duplex conformation by the core protein.
Despite these similarities, the finding that the HCV RNA genome dimerizes in vitro is
surprising, since unlike HIV-1, the HCV genomic RNA is believed to be monomeric.
Thus, it is likely that in the context of HCV, this dimerization plays a completely
different role. In addition, these results do not exclude an essential role for RNA
dimerization in other aspects of the viral life cycle, such as packaging of the viral RNA
during virion assembly.
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As mentioned earlier, it has been proposed that a fragment of the HCV DLS
sequence is involved in long-range kissing interactions with a conserved cis-acting
element located in the coding sequence of the NS5B protein (named 5BSL3.2) (43,57,),
and it has been shown that these interactions are absolutely required for RNA replication
(43,57). Since both types of kissing interactions (homodimeric between two RNA
genomes, or heterodimeric, with the 5BSL3.2 stem-loop) involve the same DLS region,
they are mutually exclusive. Thus, we propose that the DLS region might function as a
molecular switch for processes such as replication, translation and/or packaging, all
involving the same plus-strand genomic RNA. We envision a model in which
sequestration of the DLS region in a duplex dimer with another genomic RNA molecule
(promoted through the action of the core protein), excludes the DLS sequence from the
long-range kissing interaction with the 5BSL3.2 CRE required for RNA replication, thus
leading to inhibition of RNA replication and perhaps promoting packaging of the viral
RNA. It is interesting to note that the core proteins of other related viruses (such as the
flavivirus WNV, the pestivirus BVDV and the closely-related to HCV, the GBV-B)
exhibit RNA chaperone functions (47,49). Moreover, GBV-B, the only other member of
the Hepacivirus genus to which HCV belongs, has also been shown to be capable of
dimeric conformation in the presence of its core protein (49). Thus, it remains to be seen
if the dimerization of the genomic RNA is a common feature of the hepacivirus genus.
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Chapter 4: RESULTS AND DISCUSSION- MOLECULAR
CHARACTERIZATION OF HCV RNA ESSENTIAL INTERACTIONS AS
POTENTIAL THERAPEUTIC TARGETS

4.1 5BSL3.2 RNA interacts with X55 RNA via a kissing complex
In 2005, the Bartenschlager group investigated the unique stem loop 5BSL3.2,
which spans nucleotides 9263-9310 in the HCV genome, being clamped between two
other stem loop structures 5BSL3.1 and 5BSL3.3 (see figure 20). These authors showed
that the stem loop 5BSL3.2 is essential for HCV replication and through genetic
evidence, demonstrated interaction between the apical loop of 5BSL3.2 (nucleotides
9281-9287) in the coding region and the X55 (nucleotides 9540-9546) located in the
3’UTR (as shown in figure 20 in blue) and also in figure 13 of chapter 2 which shows the
detailed proposed interactions between 5BSL3.2 and X55. These interactions were
postulated to be mediated by kissing complex formation; however this proposal could not
be verified directly by NMR spectroscopy. The group also speculated that a chaperoning
protein, most probably NS5B, aids the proposed kissing loop interaction (57).
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Figure 20: Region of HCV genome revealing the location of 5BSL3.2 stem loop and its proposed
interactions with X RNA (57).
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As discussed in chapter 3, we showed that X55 RNA located in the 3’ UTR
(nucleotides 9537 – 9540 in the HCV genome) is responsible for initiation of the genomic
homodimerization via a kissing complex, which is converted to a stable duplex by the
HCV chaperoning core protein.
Given that X55 RNA uses the same stretch of nucleotides to interact with either,
5BSL3.2 or with another X55 RNA molecule, it is of interest to determine whether X55
has a similar affinity for the two interactions, being able to switch between them at
different stages of the HCV life cycle. Therefore, we decided to analyze at the molecular
level the proposed kissing interactions between 5BSL3.2 and X55 RNAs and in these
studies we have used the full-length 5BSL3.2 (48 nt, spanning the sequence 9263-9310 in
the HCV genome).
Native gel electrophoresis studies. The formation of RNA kissing complexes
requires Mg2+ ions (65,66); thus, we first inquired whether X55 RNA forms a
heterodimer with the full-length 5BSL3.2 (48 nt) in a magnesium buffer, or if it
homodimerizes via a kissing complex with another X55 RNA.

X55 Homodimer (110 nts)
X55-5BSL3.2 Heterodimer (103
nts)

X55 monomer (55 nts)
5BSL3.2 (48 nts)
1

2

3

Figure 21: 10% TBM gel with 10 mM MgCl2. All RNA samples (15µM) were treated with 10 mM
MgCl2. Lane 1-Wild type full length 5BSL3.2; Lane 2-Wild type X55; Lane 3-Wild type full length
5BSL3.2 + X55
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As shown in figure 21 in a native TBM gel in the presence of 10 mM MgCl2,
there is a single band for 5BSL3.2 (lane 1), while X55 as expected (lane 2) shows a lower
monomeric band (45) and an upper band corresponding to a homodimeric kissing dimer
(110 nts). However, when 5BSL3.2 and X55 are mixed in equimolar concentrations (lane
3, figure 2), besides the monomeric bands of 5BSL3.2 and X55, two other bands of
higher molecular size are apparent. Out of the two high molecular size bands in lane 3
figure 21, the uppermost band corresponds to the X55 homodimer of 110 nts (compare
with lane 2, figure 21), whereas the second band from the top in lane 3 corresponds to a
molecular size of 103 nts for heterocomplex of 5BSL3.2 and X55. These results clearly
indicate that X55 RNA is capable of forming both the X55 homodimer and the 5BSL3.2X55 heterocomplex simultaneously. Also, we show here that the formation of the
heterocomplex does not require the presence of a chaperoning protein.
Despite the above results that the two interactions coexist, a certain degree of
ambiguity still remains, considering the fact that the initiation sequence required for X55
homodimerization (nucleotides 9537– 9540) overlaps with the X55 sequence required for
the interaction with 5BSL3.2 (nucleotides 9540 – 9546). Moreover, since the sequences
for both interactions overlap, a tri-complex formed by two X55 and one 5BSL3.2) could
not exist due to steric hindrance. Thus, in order to be able to be engaged in both
interactions, it is likely that the monomeric X55 can exist in more than one conformation.
Therefore to investigate the possible conformations adopted by X55 RNA, we
analyzed X55 RNA in higher percentage gels containing varying MgCl2 concentrations in
the range of 1 mM to 10 mM. As is seen in figure 22A, the monomeric form of X55
appears to be resolved into 2 bands at lower concentrations of 1 and 5 mM MgCl2. The
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coexistence of X55 homodimer complex and the 5BSL3.2 –X55 heterodimer complex
was also analyzed at varying MgCl2 concentrations. As seen in figure 22B at all MgCl2
concentrations investigated (lanes 3, 6 and 9), two bands are apparent for the mixture of
X55 and 5BSL3.2, one corresponding to the homodimer X55-X55 and the second to the
5BSL3.2-X55 heterodimer. This further confirms that X55 exists in equilibrium between
2 conformations with one of the 2 conformations contributing to the X55-X55
homodimer and the other to the X55-5BSL3.2 heterocomplex formation, respectively.
1mM MgCl2

A.

5mM MgCl2

10mM MgCl2

X55 Homodimer (110 nts)

X55 Homodimer (110 nts)

X55 monomer (55 nts)
Conformation 2
X55 monomer (55 nts)

Conformation 1
X55 monomer (55 nts)

X55 Conformation 2
X55 Conformation 1
5BSL3.2
2

3

X55 +
5BSL3.2

X55 Dimer (110 nts)
X55-5BSL3.2(103 nts)

X55 Dimer (110 nts)
X55-5BSL3.2(103 nts)

1

X55

X55 +
5BSL3.2

5BSL3.2

10mM MgCl2
5BSL3.2

5mM MgCl2
X55 +
5BSL3.2

X55

5BSL3.2

1mM MgCl2

X55

B.

X55 Monomer
5BSL3.2
4

5

6

7

8

9

Figure 22: A- 12% TBM gel with X55 RNA in 1, 5 and 10 mM MgCl2 B- TBM gel with 1, 5 and 10 mM
MgCl2 Lane 1,4,7-Wild type full length 5BSL3.2 Lane 2,5,8-Wild type X55 Lane 3,6,9-Wild type full
length 5BSL3.2 + X55.

In addition, upon close analysis of figure 22A, it is seen that the band
corresponding to X55 conformation 1 and the homodimer band gets more intense with
increasing concentrations of magnesium suggesting that both conformation 1 and the
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homodimer band require magnesium for stability. It can also be suggested that
conformation 2 of X55 contributes towards homodimer formation since the band for X55
conformation 2 appears to be getting weaker with increasing concentration of
magnesium.
Simultaneous comparison of figure 22A with figure 22B shows that when the
mixture of 5BSL3.2 and X55 is treated with increasing concentration of magnesium, the
band for X55 conformation 1, now starts getting weaker with progressive increase in
intensity of heterodimer band of 5BSL3.2 –X55 complex suggesting they exist in
equilibrium. Band of X55 conformation 2 on the other hand seems to be maintaining
equilibrium with the homodimer band. This probably suggests that conformation 1 of
X55 contributes towards 5BSL3.2-X55 heterodimer interaction while conformation 2 is
involved in X55-X55 homodimer formation.
Having established that the conformations of X55 can be distinctly observed in
MgCl2 concentration less than 10 mM, all further TBM gels analyzing 5BSL3.2-X55
interactions were carried out in 5 mM MgCl2. To determine if the X55-5BSL3.2
heterodimer is indeed a kissing complex, we analyzed whether its formation is
magnesium dependent. The kissing complex conformation is metastable and depends on
the presence of Mg2+ ions, thus, it will dissociate into monomers while migrating through
a TBE gel in which the Mg2+ ions are chelated by EDTA (65, 66). Therefore, we ran two
parallel gels, one in TBM in the presence of 5 mM MgCl2 (figure 23B) and one in TBE
that contained EDTA (figure 23A). In addition, we analyzed the effect of the core peptide
on the mixture of 5BSL3.2 and X55 RNAs. X55 RNA and 5BSL3.2 RNA were snapcooled and two identical sets of samples were prepared. Each set had 4 samples (free
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5BSL3.2, free X55, 5BSL3.2 with X55 in equimolar ratio and 5BSL3.2 with X55 in
equimolar ratio in presence of core peptide) and was prepared in the presence of 5 mM
MgCl2. One set of the four-samples was run in a TBM gel, whereas the second set of the
four samples (post treatment with magnesium) was run in a TBE gel containing no
magnesium.
A.
.

B.

TBE

TBM

X55 Homodimer
X55-5BSL3.2
Heterodimer

X55 Conformation 2
X55 Conformation 1
5BSL3.2
1

2

3

4

5

6

7

8

9

10

Figure 23: A- TBE gel. 15µM samples preincubated with 5mM magnesium were loaded in each well.
Lane 1-Wild type full length 5BSL3.2 ; Lane 2-Wild type X55; Lane 3- 5BSL3.2 + X55; Lane 45BSL3.2 + X55 preincubated with magnesium and treated with core 2BD and proteinase K; Lane 55BSL3.2 + X55 preincubated with magnesium and incubated at 55°C for 2.5 hrs.
B- TBM gel. 15µM samples preincubated with 5mM magnesium were loaded in each well : Lane 1-Wild
type full length 5BSL3.2; Lane 2-Wild type X55; Lane 3- 5BSL3.2 + X55 ; Lane 4-5BSL3.2 + X55
preincubated with magnesium and treated with core 2BD and proteinase K; Lane 5- 5BSL3.2 + X55
preincubated with magnesium and incubated at 55°C for 2.5 hrs.

As shown in figure 23A, lane 1 and figure 23B lane 5, the free 5BSL3.2 sample
forms monomeric bands in both TBE and TBM gel respectively. In agreement with
earlier studies (45), the free X55 sample forms the monomeric and homodimeric kissing
complex band in the TBM gel (figure 23B lane 7) but it is dissociated to a single
monomeric band in the TBE gel (figure 23A lane 2) indicating its magnesium
dependence. In the TBM gel, the 1:1 mixture of 5BSL3.2 and X55 (figure 23B, lane 8)
shows besides the bands for monomeric X55 and monomeric 5BSL3.2, two higher
molecular size bands corresponding to the homodimer (topmost band in lane 8) and the
heterocomplex (second to the topmost band in lane 8). However the same mixture of
5BSL3.2 and X55 in a TBE gel (figure 23A lane 3) shows exclusively the monomeric
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bands and no high molecular size band, clearly indicating that both the homodimer
complex and the heterocomplex are magnesium dependent, being kissing complexes.
What is most interesting is that in the presence of the core protein, in the TBE and TBM
gel (figure 23A lane 4 and figure 23B- lane 9 respectively), the homodimer complex band
becomes more intense and 5BSL3.2 reappears as a monomeric band. Our earlier results
indicate (45) that the metastable magnesium dependent kissing X55 homodimer complex
gets converted to the more stable magnesium independent X55 duplex in the presence of
the core protein. Thus the results from figure 23B lane 8 means that in the absence of the
core protein there exists a equilibrium between the X55-X55 homodimer and 5BSL3.2X55 heterodimer and it appears from figure 23B lane 8 that the equilibrium favors more
towards the 5BSL3.2-X55 heterodimer (compare the intensities of the heterodimer and
homodimer band). This is also obvious from the lower Kd of 5BSL3.2-X55 interaction
(42.3 ±6.3 nM) shown later in figure 24B than the Kd for X55-X55 interaction (318 ± 58
nM) in figure 18A of chapter 3. However, in the presence of the core protein, the
equilibrium that favored 5BSL3.2-X55 heterodimer kissing complex is completely
shifted towards the more stable X55 homodimer duplex, resulting in the release of free
monomeric 5BSL3.2 (figure 23A lane 4 and figure 23B lane 9). These results strongly
suggest that X55 probably functions as a molecular switch in the HCV life cycle, wherein
in the absence of the core protein the replication favorable heterodimer interaction
between 5BSL3.2-X55 is favored. And once enough core protein is produced, the X55 is
switched from the heterodimer to the X55 homoduplex, thus presumably making
replication less favorable.
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Also, evident from figure 23 is that in presence of EDTA (which chelates the
magnesium) the X55 monomer exists in a single conformation (figure 23A lane 2) while
in presence of magnesium the X55 monomer clearly shows 2 conformation bands (figure
23B lane 2). This means that one of the alternate monomeric conformations of X55
requires the presence of magnesium for stability. Based on this, one may speculate that
probably out of the 2 alternate conformations predicted by the Darlix group (figure 6),
(47) maybe X RNA-2 (which is predicted as an extended duplex for the X55 region) with
its greater base pairing than XRNA-1 conformation, is the more stable conformation that
exists even in the absence of magnesium. This X RNA-2 conformation with its
palindromic sequence in the exposed state presumably initiates homodimer formation.
The second monomeric conformation that appears only in the presence of magnesium and
which presumably is the X55 conformation that interacts with 5BSL3.2 (which means
that it needs its sequence GCUGUGA either completely exposed or at least for the most
part exposed) could be something that either looks like XRNA-1 from Darlix group
(figure 6)

wherein the GCUGUGA sequence for the most part is exposed (47) or a

completely different conformation as predicted by Bartenschlager group wherein the
GCUGUGA sequence is completely exposed.
Fluorescence spectroscopy studies. To obtain quantitative information about the
kissing complex intermediate formed between X55 RNA and 5BSL3.2 RNAs, we used
fluorescence spectroscopy. In this assay, the highly fluorescent purine analog 2aminopurine (2AP) replaced the adenine at position 21 in the apical loop of the 5BSL3.2
sequence UCACAGC (position 9283 in the full length HCV genome) (circled in red in
figure 13 of chapter 2). The 2-AP steady state fluorescence is very sensitive to its
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microenvironment, being quenched by stacking interactions (68). Thus, if a kissing
complex is formed by X55 RNA with the apical loop of 5BSL3.2 in the presence of
MgCl2, the steady-state fluorescence of the 2AP reporter will be quenched due to the
change in its microenvironment from a single-stranded loop nucleotide (figure 13 of
chapter 2) to a base-paired stacked nucleotide in the kissing complex. Nanomolar
increments of wild type X55 RNA were titrated into a fixed concentration of 5BSL3.2. In
this experiment we needed to consider the possibility that the X55 RNA could also form
homodimers in the presence of MgCl2. We employed TBM native gel electrophoresis to
demonstrate that under the low concentrations used in the fluorescence spectroscopy
assay (nanomolar range) free X55 exists primarily in a monomeric conformation (figure
24A lanes 2, 5 and 8) and that when mixed in an equimolar ratio with 5BSL3.2, the
5BSL3.2–X55 heterodimeric kissing complex is dominant (figure 24A, lanes 3, 6 and 9).
The titration of the 2-AP labeled 5BSL3.2 (76 nM in 1 mM cacodylic acid pH 6.5
and 5 mM MgCl2) with nanomolar increments of the complementary unlabeled construct,
wild type X55 RNA, resulted in a decrease in the steady-state 2-AP fluorescence
emission at 371 nm (figure 24B), due to the base stacking interactions arising when the
2AP in the labeled RNA (5BSL3.2_AP) and the uracil in the unlabeled complementary
RNA (X55) base pair. A dissociation constant of 42.3±6.3 nM was determined for the
heterodimeric kissing complex formed by X55 and 5BSL3.2 by fitting the binding curve
illustrated in figure 24B with equation 3, materials and methods. It is clear that the X555BSL3.2 heterodimeric kissing complex has a much lower dissociation constant (Kd =
42.3 ± 6.3 nM) than the X55-X55 homodimeric kissing complex (Kd = 318 ± 58). This
result is consistent with our native gel electrophoresis results, which showed a more
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intense band for the heterodimeric versus the homodimeric kissing complex (figure 23B,
lane 8). To confirm the specificity of the fluorescence spectroscopy assay, in a separate
control experiment we titrated the 2AP labeled 5BSL3.2 with a non-complementary 37 nt
RNA named IIId that served as a control (figure 24B red points). As expected, since IIId
RNA does not have a complementary sequence to 5BSL3.2 apical loop, no significant
quenching was observed for the 2-AP steady-state fluorescence.
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Figure 24: A- TBM gel and samples with 5 mM MgCl2. Lane 1-0.05 µM wild type full length 5BSL3.2;
Lane 2-0.05 µM wild type X55; Lane 3- 0.05 µM 5BSL3.2 + 0.05 µM X55 preincubated with magnesium
Lane 4-0.1 µM 5BSL3.2; Lane 5- 0.1 µM X55; Lane 6- 0.1 µM 5BSL3.2 + 0.1 µM X55 preincubated
with magnesium; Lane 7- 0.3 µM 5BSL3.2; Lane 8- 0.3 µM X55; Lane 9- 0.3 µM 5BSL3.2 + X55
preincubated with magnesium.
B- Fluorescence spectroscopy of wild type 5BSL3.2 with wild type X55 (in black) and control IIId (in red)

4.2 Both Alt and IIId interact with 5BSL3.2 via a kissing complex
In 2008, the Evans group performed in silico predictions and mutational analysis
to investigate a long range interaction between the internal bulge loop of 5BSL3.2
(GCCCG motif, nucleotides 9297-9201 in the HCV genome) and an unpaired sequence
nt 9106 – nt 9123 located approximately 200 nts upstream (named Alt) and proposed this
interaction to be essential for replication (see figure 25 shown in brown).
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Figure 25: Mustard is the interaction between IIId and Internal bulge loop of 5BSL3.2 and in brown is
interaction between ALT and internal bulge loop of 5BSL3.2

In 2009, the Berzal-Herranz group reported that the IRES located in the 5’-UTR
of the HCV genome associates with the 3’ end of the coding region of HCV genome in
the presence of low magnesium concentrations and proposed that these interactions may
be essential for the translation of the viral proteins. In their study, the group used anti
sense transcripts against the full-length IIId domain (located in the IRES of the HCV
genome) and the full length 5BSL3.2 (located in the 3’ end of the coding region of HCV
genome) to demonstrate that IIId and 5BSL3.2 were the key elements in the long range
interaction. Furthermore, using mutant versions of 5BSL3.2 (GCCCG →CGGGC) and
IIId (CGGGC → GCCCG) (see figure 25 shown in green), they proposed the active
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motifs in the interactions to be the apical loop of IIId and the internal bulge loop of
5BSL3.2 (GCCCG motif).
Interestingly, the same motif GCCCG located in the internal bulge loop of
5BSL3.2 has been predicted using mutational constructs to have interactions with two
different regions: one, the Alt sequence, located 200 nts upstream of 5BSL3.2 and the
other, the IIId domain, located in 5’-UTR of the HCV genome, respectively. However,
given the fact that 5BSL3.2 is a crucial cis-regulating element within the HCV life cycle
and also the high conservancy of the GCCCG motif in the internal loop of 5BSL3.2, any
mutation in its sequence can be deleterious to its native structure and folding and thus, its
mutant versions may be less suitable in identifying the correct active motifs in important
interactions. Additional data supporting this argument comes from the study by Evans
group who constructed a mutated 5BSL3.2 wherein the internal bulge motif GCCCG was
point mutated and replaced with GCUCG. This mutated 5BSL3.2 clearly has its internal
bulge loop sequence complementary to the apical loop of IIId domain, as well as to the
Alt sequence and thus, would be expected to function equivalent to a wild type. However,
the point-mutated 5BSL3.2 was functionally impaired and caused inhibition of new
colonies.
In addition, thermodynamic predictions by the Berzal-Herranz group suggested
that the 5BSL3.2 –IIId interacting loops might be extended to a duplex due to sequence
complementarity (figure 26 right.).
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Figure 26: Predicted kissing interaction and duplex formation between 5BSL3.2 and IIId as per BerzalHerranz.

Therefore, in order to investigate the above mentioned proposed interactions at
the molecular level, we performed native gel electrophoresis experiments using the wild
type 5BSL3.2, IIId domain and Alt sequences.
Figure 27B shows the interaction between full-length 5BSL3.2 and IIId in a TBM
gel containing 0.5 mM MgCl2. Both 5BSL3.2 (48 nt) and IIId (37 nt) individually
migrate as monomers (lanes 5 and 6, respectively), whereas when mixed in a 1:1 ratio, a
higher band appears, corresponding to the 5BSL3.2-IIId complex (figure 27B, lane 7). To
examine if the 5BSL3.2-IIId complex was magnesium dependent, 5BSL3.2 and IIId
samples were analyzed in a TBE gel (figure 27A). Once again individually 5BSL3.2 and
IIId migrated as monomers as shown in lanes 1 and 2 of figure 27A respectively, while
the 5BSL3.2-IIId mixture which showed a higher complex species in the presence of
magnesium was resolved into monomers in the TBE gel (figure 27A, lane 3), indicating
that the formation of the 5BSL3.2-IIId complex is magnesium dependent. The occurrence
of 5BSL3.2-IIId complex at low magnesium concentration is in agreement to the results
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by Berzal-Herranz group; however this study provides primary evidence on the
magnesium dependence property of the 5BSL3.2–IIId complex, thus a kissing complex.
To test whether the metastable magnesium dependent 5BSL3.2-IIId kissing
complex is converted to a stable magnesium independent duplex in the presence of a
chaperoning protein, we treated the 5BSL3.2-IIId kissing complex (in presence of
magnesium) with the HCV chaperoning core peptide and analyzed the peptide-treated
5BSL3.2-IIId mixture in both TBM and TBE gels. If the 5BSL3.2-IIId complex is
converted to a duplex in the presence of the HCV core peptide, then in a TBE gel the
mixture of 5BSL3.2-IIId should exist as a dimer and would not be expected to dissociate
into its monomers. As shown in figure 27B lane 8, the peptide treated 5BSL3.2-IIId
mixture appeared as a complex in a TBM gel but was resolved into its respective
monomers in a TBE gel (figure 27A lane 4), indicating that the kissing complex is not
converted to the stable duplex.
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Figure 27: A- TBE gel. Samples preincubated with 0.5 mM magnesium were loaded in each well. Lane 115 µM wild type full-length IIId; Lane 2-15 µM Wild type 5BSL3.2; Lane 3- 15 µM 5BSL3.2 + 15 µM
IIId preincubated with magnesium; Lane 4- 15 µM 5BSL3.2 + 15 µM IIId preincubated with magnesium
and treated with core 2BD and proteinase K;
B- TBM gel. Samples preincubated with 0.5 mM MgCl2. Lane 5-15 µM wild type full length IIId; Lane 615 µM wild type 5BSL3.2 Lane 7- 15 µM 5BSL3.2 + 15 µM IIId preincubated with magnesium; Lane 815 µM 5BSL3.2 + 15 µM IIId preincubated with magnesium and treated with core 2BD and proteinase K.

In a similar manner using TBM and TBE native gel electrophoresis, we analyzed
the interactions between 5BSL3.2 and Alt. In a TBM gel, (figure 28B, lanes 4 and 5) both
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free Alt and 5BSL3.2 migrate as monomers, whereas when mixed in equimolar ratios a
higher molecular weight band appears, corresponding to the 5BSL3.2-Alt complex (lane
6). However, when the 1:1 ratio of 5BSL3.2-Alt complex was analyzed in a TBE gel
(figure 28A lane 3), the mixture was resolved into its respective monomers, thereby
demonstrating its magnesium dependence and confirming the interaction as a kissing
complex.
TBE

A.
.

TBM

B.
5BSL3.2-Alt

5BSL3.2

Alt

1

2

3

4

5

6

Figure 28: A- TBE gel. Samples were preincubated with 0.5mM MgCl2. Lane 1- 15 µM ALT;
Lane 2- 15 µM wild type 5BSL3.2; Lane 3- 15 µM 5BSL3.2 + 15 µM ALT;
B- TBM gel with 0.2 mM MgCl2. Lane 4-15 µM wild type full-length Alt; Lane 5-15 µM wild type
5BSL3.2; Lane 6- 15 µM 5BSL3.2 + 15 µM Alt.

In addition, to confirm the active sequences that participate in the kissing
interactions between 5BSL3.2 and IIId, or 5BSL3.2 and Alt, a 24 nt 5BSL3.2 containing
only the apical stem-loop and devoid of the internal bulge (5BSL3.2 short, figure 29A)
was used. Furthermore, the interaction of IIId and Alt with a truncated version of 38 nt
5BSL3.2 (5BSL3.2 TRUNC, figure 29B) that contained the apical loop and the internal
bulge sequence but is devoid of five base pairs in the lower stem region and which is also
the same sequence used by Bartenschlager group for NMR studies, was analyzed (57).
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Figure 29. A. 5BSL3.2 short (24nts) B. 5BSL3.2 TRUNC (38nts) C. 5BSL3.2 TRUNC (38nts) as per RNA
structure. D. TBM gel. All RNA samples (15µM) was preincubated with 0.5mM MgCl2. Lane 1- IIId,
Lane 2- 5BSL3.2 short, Lane 3- 5BSL3.2 short + IIId, Lane 4- Alt, Lane 5- 5BSL3.2 short, Lane 65BSL3.2 short + Alt, Lane 7- IIId, Lane 8- 5BSL3.2TRUNC, Lane 9- 5BSL3.2 TRUNC + IIId, Lane 10Alt, Lane 11- 5BSL3.2 TRUNC, Lane 12- 5BSL3.2 TRUNC + Alt

As seen in figure 29D, in a TBM gel in lane 1 and 2 both full-length IIId and
5BSL3.2 short, when loaded individually, migrate as monomers. But when an equimolar
ratio of 5BSL3.2 short and IIId was loaded (figure 29D lane 3), the 5BSL3.2 short and
IIId migrated as their monomeric bands and no higher molecular weight complex was
observed. This result clearly indicates that IIId is unable to react with 5BSL3.2 short
since it is devoid of the complementary internal bulge motif GCCCG.
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Since it appears that the internal bulge motif of 5BSL3.2 (GCCCG) and apical
loop of IIId is involved in the 5BSL3.2-IIId complex, it was expected that the 38nt
truncated version of 5BSL3.2 called 5BSL3.2 TRUNC (figure 29B) which contains the
internal bulge motif but has the five base pairs in the lower stem region deleted, would be
able to interact with IIId. However, as seen in figure 29D lane 6, IIId and 5BSL3.2
TRUNC migrate as monomers (compare with lane 4 and 5 which contains monomeric
IIId and 5BSL3.2 TRUNC respectively) and do not show any higher complex species.
Upon further analysis using RNA secondary structure prediction software named RNA
structure, we found that 5BSL3.2 TRUNC can form an alternative structure (figure 29C),
rather than the structure in figure 29B, wherein it loses its native internal bulge loop
motif, and thus loses its ability to interact with IIId or Alt.
In a similar manner, to evaluate whether 5BSL3.2 short and 5BSL3.2 TRUNC
can interact with Alt, their mixtures were examined in a 0.5 mM MgCl2 TBM gel. Figure
29E lane 9, which contains an equimolar ratio of Alt and 5BSL3.2 short, contains no
higher complex species and both Alt and 5BSL3.2 short migrate as monomers (compare
with lane 7 and 8 which contain monomeric Alt and 5BSL3.2 short respectively). Alt
also showed no higher complex band when mixed in an equimolar ratio with 5BSL3.2
TRUNC (figure 29E lane 12).
All of these results clearly indicate that 5BSL3.2 requires its internal bulge loop
for kissing interaction with both the IIId domain as well as with Alt. In addition, these
experiments, which used wild type sequences of the interacting regions, provide
primarily direct evidence of kissing complex formation for the two indirectly
demonstrated interactions between 5BSL3.2-IIId and 5BSL3.2-Alt.

62

Having confirmed the above kissing interactions, the next most relevant question
that arose was that since the HCV genome carries 5BSL3.2, IIId and Alt sequences all in
a single strand, which of the two 5BSL3.2-Alt or 5BSL3.2-IIId interactions is dominant?
To address this question, we investigated the interactions of 5BSL3.2 with Alt and IIId
simultaneously by TBM native gel electrophoresis. Figure 30, lane 1 and 2 contains
monomeric wild type IIId and full-length 48 nt 5BSL3.2 respectively. Lane 3, which
contains an equimolar ratio of IIId and 5BSL3.2, shows the higher molecular weight
species of 5BSL3.2-IIId complex. Lanes 6 and 7 contain full-length 48 nt 5BSL3.2 and
Alt, respectively, which migrate as monomers, whereas lane 8 contains their 1:1
equimolar ratios which migrates as a dimer. Lane 4, contains a mixture of all three
RNAs- 5BSL3.2, IIId and Alt in an 1:1:1 ratio, elucidating that the 5BSL3.2-IIId
interaction dominates over the 5BSL3.2-Alt interaction, based on the fact that the
monomeric Alt band is more intense in lane 4 (compare with lane 6 and 7), probably due
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to the IIId interacting with 5BSL3.2 and thus the Alt remains as a monomer.
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Figure 30: 15% TBM gel with samples preincubated with 0.5mM MgCl2 Lane 1-15 µM wild type full
length IIId; Lane 2-15 µM wild type 5BSL3.2; Lane 3- 15µM wild type 5BSL3.2 + 15 µM IIId;
Lane 4- 15 µM Alt + 15 µM 5BSL3.2 + 15 µM IIId; Lane 5- 15µM wild type 5BSL3.2 + 15 µM Alt;
Lane 6- 15 µM 5BSL3.2; Lane 7- 15 µM Alt.
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In this chapter we have analyzed at the molecular level three important
interactions of 5BSL3.2. And so far, it is evident that 5BSL3.2 –IIId interaction is
dominant over the 5BSL3.2-Alt interaction. Thus the next question that we asked was
what impact the internal bulge loop interactions of 5BSL3.2 (with either IIId or Alt) has
on the apical loop interaction of 5BSL3.2 (with X55). To analyze if the IIId or Alt
interaction with the internal bulge loop of 5BSL3.2, interferes with the 5BSL3.2 apical
loop interaction with X55, we conducted fluorescence spectroscopy studies.
For this we incubated IIId or Alt with the fluorescent 5BSL3.2_21AP, in an
equimolar ratio in the presence of 5mM magnesium to allow 5BSL3.2_21AP–IIId or
5BSL3.2_2AP-Alt complexes to preform. Subsequently, nanomolar increments of X55
were titrated into the 5BSL3.2_21AP–IIId (or 5BSL3.2_2AP-Alt) mixture and the change
in the steady-state fluorescence of 2AP was monitored. Earlier we had determined the
dissociation constant (Kd) of the 5BSL3.2-X55 kissing complex to be 42.3 ± 6.3 nM. If
the IIId (or Alt) binding to the internal bulge loop of 5BSL3.2 has any effect on the
5BSL3.2 apical loop interaction with X55, it is expected that the Kd value will change.
As shown in figure 31A and B, in the presence of IIId, the Kd value of 5BSL3.2 –
X55 complex is changed from 42.3 ± 6.3 nM to 77 ± 8.5 nM. Similarly, the Kd value of
5BSL3.2 –X55 complex is changed from 42 ± 6.3 nM to 80 ± 2.6 nM in the presence of
Alt. The Kd values for 5BSL3.2-X55 interaction have almost doubled in the presence of
IIId or Alt, indicating some local hindrance posed by either Alt or IIId. However, in these
studies we worked with truncated RNAs; thus, these interference effects might be
amplified in the context of the entire HCV genome, especially for the IIId interactions
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with 5BSL3.2, considering that the entire 5’-UTR will be brought into the close
proximity of the 5BSL3.2 coding region, limiting the 5BSL3.2 range of interactions.
A.

Kd = (80.4 ± 2.6) nM

B.

Kd = (77.3 ± 8.5) nM

Figure 31: A. Fluorescence spectroscopy of 5BSL3.2_21AP with wild type X55 in the presence of Alt
B. Fluorescence spectroscopy of wild type 5BSL3.2 with wild type X55 in the presence of IIId

4.3 Conclusions: A possible model for HCV life cycle
We provide direct experimental evidence for three essential kissing interactions in
which the highly conserved 5BSL3.2 element is involved: 5BSL3.2 - X55, 5BSL3.2 IIId and 5BSL3.2 –Alt, as well as for X55-X55 homodimerization. The dissociation
constant for the homodimer complex X55 - X55 has been determined in this study to be
318 ± 58 nM (figure 18C), whereas the dissociation constant of the 5BSL3.2–X55
complex was determined to be 42.3 ± 6.3 nM (figure 24B). The Berzal-Herranz group
reported the dissociation constant of 5BSL3.2-IIId complex to be 49.5 nM. However, the
5BSL3.2 - IIId interaction occurs at lower magnesium concentrations (0.2-0.5 mM) than
those required for the 5BSL3.2 - X55 interactions, (1-5 mM) suggesting that the 5BSL3.2
has higher affinity for IIId than for X55. In addition, from figure 30, lane 4, it is evident
that 5BSL3.2-IIId interaction dominates the 5BSL3.2–Alt interaction. Based on these
results the proposed order of interactions, based on their strength, is shown in Table 4.
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Table 4: List of interactions investigated in this study

Interactions

Kd (nM)

Magnesium Concentration
(mM)

Strength

X55-X55 Homodimer

326

5-10

+

5BSL3.2-X55
Heterodimer
Alt

43

1-5

++

-

0.5

+++

IIId

49

0.5

++++

Based on this data, we propose the following model which speculates on the
possible biological role of these interactions in the context of the HCV life cycle (figure
32): in an HCV infection, following the entry of the viral genome into the hepatocyte, the
5BSL3.2-IIId interaction causes the circularization of the viral RNA (as shown in figure
32B).
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Figure 32: A. Schematic representation of the full-length HCV genome in which for simplicity only the
secondary structures pertinent to the current model are shown: 5’-UTR-green; coding region-red; 3’UTRpurple B. IIId interacts with internal bulge loop of 5BSL3.2, thereby leading to the circularization of HCV
RNA. C. Represents the circularized HCV RNA and the ribosomes shown in brown initiate translation.
D. When the ribosomes reach the point of 5BSL3.2-IIId interaction the kissing complex is disrupted and
the IIID is released. E. Upon release of the IIId from the 5BSL3.2-IIId complex, Alt inititaes interaction
with the internal bulge loop of IIId and this is further strengthened by X55 interaction with the apical loop
of 5BSL3.2. This dual interaction completely prevents IIId interaction with 5BSL3.2. Both the 5BSL3.2Alt and 5BSL3.2-X55 intercation are known to be important for replication. Thus replication begins.
F. The core protein synthesized from the translation in figure 33A, now seeks XRNA and pushes it to
genomic dimerization, thus disrupting 5BSL3.2-X55interaction and halting replication. IIId can now
interact with internal bulge loop of 5BSL3.2 and restart translation or the dimerized HCV RNA may be
packaged.
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The ribosome, which is known to have a strong affinity for the III domain, (86)
gains access to the HCV RNA and soon reaches the AUG codon, upon which translation
begins as shown in figure 32C. The ribosome reads the HCV RNA in the 5’ to 3’
direction, and when it approaches the point where the 5BSL3.2 internal bulge loop
interacts with IIId, the 5BSL3.2-IIId kissing interactions are disrupted as illustrated in
figure 32D.
It is likely that the Alt sequence is not available for interactions with the internal
loop of 5BSL3.2 during translation, due to the location of both sequences in the coding
region, being probably engaged in interactions with the ribosomes. Once the “last”
ribosome starts moving further down the 5BSL3.2 sequence, the X55 probably gains
access to the terminal loop of 5BSL3.2 binding it and preventing the re-formation of the
5BSL3.2-IIId complex. This in turn could facilitate the 5BSL3.2–Alt interaction as
shown in figure 32E, because now, in the absence of the interactions with the 5’-UTR,
the 5BSL3.2 becomes accessible to the interactions with the 3’-UTR. This dual
interaction of 5BSL3.2–Alt and 5BSL3.2–X55, simultaneously prevents the 5BSL3.2IIId interaction inhibiting translation and shifting the viral RNA to a replication mode.
This model is supported by the experimental evidence that both, the 5BSL3.2-X55 and
5BSL3.2-Alt interactions are essential for the viral replication (56,57). When sufficient
viral core protein is synthesized, the HCV core protein initiates genomic dimerization as
shown in figure 32F. This means the 5BSL3.2-X55 interaction is disrupted and X55 now
becomes involved in dimerization with another HCV genome, and as a result the HCV
replication is inhibited. This could shift the HCV RNA from the replication mode to the
packaging mode, producing new active HCV virions.
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Chapter 5: RESULTS AND DISCUSSION - DESIGN AND ANALYSIS OF
PEPTIDE NUCLEIC ACID THAT INHIBIT HCV TRANSLATION AND
REPLICATION

5.1 Peptide nucleic acids as potential therapeutics against HCV replication
The essential kissing interactions within the HCV RNA investigated in chapters 3
and 4, involve motifs that are 100% conserved among HCV genotypes (56, 57). Given
the highly mutational nature of HCV, these 100% conserved motifs could serve as
important targets for anti HCV therapeutic strategies.
Among the currently available diverse anti-viral therapeutic strategies,
oligonucleotide based antisense technology has become the center of biomedical research
in the last few decades. In antisense technology (82), the target RNA is either knocked
out or made unavailable by hybridizing it with a complementary oligonucleotide
sequence in a parallel or antiparallel fashion using native Watson-Crick base pairing.
Since the recognition of antisense technology in 1970’s (83), several approaches have
been developed to improve the efficiency of antisense oligonucleotides with respect to
nuclease tolerance, tighter hybridization with target RNA or DNA, cell permeability,
stability, specificity, nucleotide composition and the length of the oligonucleotides (82
and references therein). Among the third generation of modified and improvised
antisense oligonucleotides, peptide nucleic acids (PNA) - a synthetic analogue of DNA
and RNA, seem to show great potential as a therapeutic tool. To date the potential of
PNA has extensively been investigated against different HIV life stages such as reverse
transcription (84, 85, 86), integration (84, 87, 88), transactivation (84, 89) and
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dimerization (84, 90) in both cell culture as well as cell free assays (84). However in the
HCV system, the potential of PNA as a therapeutic tool has been hardly explored.
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Figure 33: A- Peptide nucleic acid B- Naturally occurring nucleic acid C- γ substituted

PNA

Initially reported in early 1990’s (91, 92), PNA has a pseudopeptide backbone of
N-(2-aminoethyl) glycine units that are connected by peptide bonds (figure 33A). The
nucleobases (purine and pyrimdines) are linked to the backbone by methylene carbonyl
bonds. Unlike the naturally occurring nucleic acids (figure 33B) which have a sugar
phosphodiester backbone that gives the DNA and RNA its overall negative charge, the
unique N-(2-aminoethyl) glycine backbone of PNA makes it neutral (102,103). Thus, in
PNA-RNA or PNA-DNA heteroduplex state, the binding is much stronger than observed
for its DNA-DNA or RNA-RNA homoduplex counterpart, due to reduction in
electrostatic repulsion among phosphate groups. Moreover the unique backbone of PNA
also renders it the ability to evade recognition and degradation by both proteases and
nucleases (92, 93). Although all of this makes PNA a lucrative therapeutic agent, it still
has its limitations. The neutral backbone of PNA makes the molecule hydrophobic, as a
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result of which PNA becomes less soluble and folds into complex globular structures and
sometimes even aggregates (94, 95). This conformational collapse of PNA makes it less
available for hybridization with its target sequence and thus reduces its efficiency.
Despite several approaches to improve on the rigidity and hybridization properties of
PNA, very few studies (that are either too elaborate or use relatively expensive starting
materials), have shown any progress (94 and references therein).
In 2006, the Ly group synthesized and investigated a simple backbone modified
PNA based on the concept of preorganization (94). The concept of preorganization was
first introduced by Cram in 1987 (96, 97) during a study analyzing the design of small
organic guest-host hybridization complexes. Cram recognized that hybridization
complexes were entropically unfavorable and to address this problem he introduced the
concept of "preorganization" (96). As per this concept, if the interacting molecules were
to be pre-organized into their binding conformations, then during the hybridization, the
entropy loss will be reduced, thereby increasing the rigidity of the complex in terms of
stability and specificity.
The Ly group synthesized γ substituted PNA backbone which made possible
preorganization of randomly folded PNA into a right handed helix. In their study they
also showed that not only does this γ substituted PNA allow preorganization into binding
conformation but also enhances the PNA affinity and selectivity for its target sequence
(94).
To explore the therapeutic potential of γ substituted PNAs in the context of HCV,
we have developed collaboration with Dr. Ly at Carnegie Mellon University. The general
strategy was to design γ substituted PNA molecules that would disrupt the interactions
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between highly conserved regions within the HCV genome. In this study we investigated
a PNA that was designed against the HCV X RNA sequence 9539 – 9548 (figure 14 from
chapter 2), which has been shown to be involved in in vitro RNA homodimerization and
also in interactions with the 5BSL3.2 apical loop in the coding region. Although the
biological role of HCV RNA homodimerization is yet to be established, the interaction of
X RNA with 5BSL3.2 has been shown by the Bartenschlager group to be vital for the
virus replication (57). Given this dual interaction of X RNA, a 10 base PNA was
designed against X RNA, such that both the homo- and hetero- interactions of X55 RNA
with another X55 or with 5BSL3.2 would be disrupted. This PNA was synthesized and
purified in the laboratory of Dr. Ly of Carnegie Mellon University, Pittsburgh.
Currently there are only a few studies that investigated the therapeutic efficiency
of PNA against Hepatitis C virus and all of these studies analyzed PNA designed against
IRES sequences located in the 5’UTR of the HCV genome (98-100). Since this was the
first study to investigate the interactions of PNA against X55 RNA sequence located in
the 3’UTR of HCV RNA, several experimental conditions such as PNA specificity,
temperature, PNA concentration and incubation times were analyzed.
i. PNA Specificity: Of the three studies that investigated PNA efficiency against
HCV IRES sequences –the Patino group compared the use of a cylic PNA versus linear
PNA synthesized against domain IV of HCV IRES (100). Earlier the Patino group,
synthesized cyclic PNA molecules that interfered with HIV 1 genome dimerization
process and hypothesized that the pre-organized cyclic PNA probably affords advantage
over its linear analogue in terms of selectivity (101). However this approach when
applied to the HCV system, gave contradictory results, wherein the cyclic PNA showed
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lower activity than its linear analog. Also, at higher concentration the cyclic analog
introduced non-specific interactions with other RNA sequences (100).
The problem of nonspecific interactions at higher concentrations of PNA was also
observed by the Hantz group in 2008 wherein they analyzed several short PNA molecules
against the 5’UTR sequences of HCV RNA (99).
The newly synthesized PNA from the Ly group has an L-serine side chain
inserted at the γ position of the pseudopeptide backbone (figure 33C). This substitution
increases the solubility of the PNA as the hydroxyl group of the serine side chain can
form hydrogen bonds with the nearby water molecules (94). Also, it allows
preorganization of the PNA into a right handed helix (94). The efficiency of this PNA has
already been investigated by the Ly group in vitro for both RNA and DNA sequences.
However to ensure that the γ substituted PNA does not cause nonspecific interactions in
the HCV system, we analyzed the specificity of the PNA developed against X55 RNA.
All RNA samples were pretreated with 5 mM MgCl2 and their interactions with the PNA
were analyzed by TBM gel electrophoresis (figure 34A). Lanes 1, 2 and 3 in figure 34A
contain free 5BSL3.2 RNA, free X55 RNA, and their 1:1 mixture respectively, whereas
lanes 4-6 contain identical samples which were incubated for 2 hours at 37°C with 2-fold
PNA. When 5BSL3.2 was incubated with PNA (lane 5), a single band corresponding to
the monomeric 5BSL3.2 (compare with lane 1) was observed in the gel, indicating the
absence of any reactivity of 5BSL3.2 RNA with PNA. However, when the PNA was
added to its target X55 RNA (lane 6), the monomer and dimer bands of X55 RNA
disappeared, with the concomitant appearance of three new bands (compare with lane 2),
which were labeled as Band A (lowermost), Band B (middle) and Band C (uppermost).
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Our results that the PNA binds to X55, but not to 5BSL3.2 indicate that the PNA is
specific for X55 RNA. The origin of the bands A, B, and C however, is not clear. Initially
we assumed that bands A and B correspond to the PNA bound to the two monomeric
conformations of X55 RNA, whereas band C corresponds to a dimer of X55 bound by
PNA. However, this hypothesis was not confirmed experimentally, as these bands are
also present in the absence of MgCl2, wherein X55 exists in a single monomeric
conformation (data not shown). Further studies are needed to elucidate the origin of the
A, B and C bands.
One of the strategies to assign the origin of bands A, B and C would be to
examine the effect of PNA on a mutant X55 which is unable to homodimerize. What is
expected is that if the band C is due to PNA interacting with X55 homodimer then the
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5BSL3.2 + X55

X55
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mutant X55 upon treatment with PNA would not show band C.
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Figure 34A:12% TBM gel with 5 mM MgCl2. Lane 1- 5BSL3.2 (15µM) Lane 2-X55 (15µM), Lane 35BSL3.2 (15µM) +X55 (15µM), Lane 4-X55 (15µM) +5BSL3.2 (15µM) +2-fold PNA (30µM) for 2
hours at 37°C), Lane 5- 5BSL3.2 (15µM) +2-fold PNA (30µM) for 2 hours at 37°C,
Lane 6-X55 (15µM) +2-fold PNA (30µM) for 2 hours at 37°C
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Figure 34A, lane 3 contains 5BSL3.2-X55 mixture prior to incubation with PNA
and as expected the X55 homodimer and the heterodimer band is observed along with a
weak unreacted 5BSL3.2 band. Lane 4 contains 5BSL3.2-X55 mixture incubated with
PNA and it is clear that both bands corresponding to the X55-X55 homodimer kissing
complex and to the X55-5BSL3.2 heterodimer kissing complex are no longer present,
whereas the free 5BSL3.2 band increases in intensity with the concomitant appearance of
the bands A, B, C corresponding to the interactions of X55 RNA with the PNA. This
result indicates that 2-fold PNA is capable of disrupting at 37°C in a time period of 2
hours both the homo- and hetero- kissing complexes formed by X55 RNA and at 2-fold
concentration of PNA there is no visible non-specific interaction.

ii.

Concentration Dependence: The Corey group, Hantz group and the Patino

group (98-100), investigated the therapeutic potential of PNA in the concentration range
of 25 nM to 60 µM against HCV IRES in replicating conditions. Thus the precise
effective ratio of PNA to RNA is not clear. In analyzing the specificity of the PNA, we
used 2-fold PNA which was incubated for 2 hours at 37°C with the target X55 RNA.
However to narrow down the effective required PNA concentration, we treated the target
X55 RNA with increasing concentrations of PNA (0.25-fold, 0.5-fold and 1-fold PNA).
As seen in figure 34B, a single band is present in lane 1 which contains free 5BSL3.2,
two monomeric and one dimer band are present in lane 2 which contains free X55 RNA.
As expected, both the X55-X55 homodimer and the X55-5BSL3.2 heterodimer bands
are present in lane 3, as well as some unreacted free 5BSL3.2.
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Figure 34 B:12% TBM gel with 5mM magnesium. 15µM samples were pretreated with magnesium.
Lane 1- 5BSL3.2, Lane 2-X55, Lane 3-5BSL3.2+X55, Lane 4 to6-X55+5BSL3.2+PNA (0.25 to 1 fold
for 2 hours at 37°C)

But when 0.25-fold PNA is added (figure 34 B, lane 4), both the monomeric X55
bands and the X55 homodimer band disappear with the concomitant appearance of bands
A, B and a faint band C due to the interactions of X55 with PNA. The X55-5BSL3.2
heterodimer band though weaker than in lane 3, is still present in lane 4. In the presence
of 0.5-fold PNA (lane 5), the X55-5BSL3.2 heterodimer band gets weaker while the
bands A and B become more intense. Finally, upon the addition of 1-fold PNA (lane 6),
both the X55 homodimer and the heterodimer bands disappear, while the monomeric
5BSL3.2 band and the bands A, B and C caused due to X55-PNA interactions are more
intense. These results clearly indicate that at 37°C, the treatment of X55 RNA with 1-fold
PNA for 2 hours is effective in disrupting both, the X55-X55 homodimer, as well as the
X55-5BSL3.2 heterodimer interaction.
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In a clinical setting it would not always be possible to get the precise
concentration of HCV RNA within the patient hepatic cell and to maintain PNA to target
RNA ratios. Thus to be used as a therapeutic tool, the PNA would have to be effective
even at lower concentrations. From the results of figure 34 B, it is clear that even at onefourth the concentrations of the target RNA, the new γ substituted PNA was effective,
though at a lower level.
iii.

Time, Concentration and Temperature. While analyzing the effect of cyclic

PNA against HCV IRES, Corey and Hantz group performed PNA treatment for 90
minutes at 30°C (98, 99), while Patino group (100) used cell culture conditions of 37°C
and evaluated results 36-48h post PNA and target RNA transfection into cells. In our
study, to determine the optimum conditions (concentration, temperature and incubation
period) required for PNA to disrupt the X55 interactions, we incubated a preformed
kissing complex mixture of X55 and 5BSL3.2 with varying concentrations of PNA (1-6
fold) for 1-2 hrs at two different temperatures: 21°C and 37°C. We wanted to examine
the effect of cumulative changes in temperature, concentration and time on the efficiency
of the γ substituted PNA. Figure 35A lane 3 shows the mixture of 5BSL3.2-X55 prior to
PNA treatment at 21°C, and as expected, both the homo- and hetero-interaction bands of
X55 RNA are clearly visible. Lanes 4-11 contain a preformed kissing complex mixture of
5BSL3.2-X55 which was incubated with increasing concentration of PNA (1-6 fold) at
21°C for 2 hour (lanes 4-7), and for 1 hours (lanes 8-11), respectively. It is clear from the
lanes 4-7 and lanes 8-11 of figure 35A that even at lower temperature of 21°C, the PNA
is efficiently able to disrupt both homo and hetero dimer interaction at both 2 hour and 1
hour time intervals. Also, note PNA concentration as little as of 1 fold was proficient at
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21°C (Figure 35A lane 4 and lane 8) within time intervals of both 2 hour and 1 hour to
disrupt the essential homo and hetero kissing complexes formed by X55 RNA with
another X55 or with 5BSL3.2 RNA.
Figure 35B shows results for the preformed kissing complex samples of X55 and
5BSL3.2 that were incubated at 37°C with varying concentrations of PNA (1-6 fold) for
1-2 hrs. Once again we observe very similar results as seen for samples at 21°C. Figure
35B lane 3 shows the mixture of 5BSL3.2-X55 prior to PNA treatment at 37°C. And as
expected, the homo and hetero interaction bands are clearly visible. Lanes 4-7 and lanes
8-11 contain preformed kissing complex mixture of 5BSL3.2-X55 treated with increasing
concentration of PNA (1-6 fold) at 37°C for 2 and 1 hour respectively. It is clear from the
lanes 4-7 and lanes 8-11 of figure 35B, the PNA is efficiently able to disrupt at 37°C (as
also observed for 21°C) both homo and hetero dimer interactions within 2 hour or 1 hour
time intervals.
Apart from the observation on the efficiency of the PNA to inhibit the essential X55X55 homodimer, as well as the 5BSL3.2-X55 heterodimer interaction, it appears from
figure 35A, lane 7 and 11 (also see figure 35B lane 7 and 11), that with increasing
concentration of PNA the intensity of band C seems to increase, while bands A and B get
correspondingly weaker. For now, one can only speculate that either band C is a result of
PNA aggregation or another possibility would be that at higher concentration of PNA, the
number of PNAs present in band C (which may be PNA-X55 homodimer complex)
increases while making it most stable. Thus the equilibrium that existed between bands
A, B and C is shifted towards band C at higher concentrations of PNA. The idea of band
C being PNA aggregation is still skeptical, because if it was non-specific aggregation
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then 5BSL3.2 treatment with 2-fold PNA (figure 33, lane 5) should also have shown the
presence of band C. But the absence of band C upon treatment of 5BSL3.2 with PNA
suggests that probably band C is not a result of aggregation.

5BSL3.2 + X55 + 6X PNA

5BSL3.2 + X55 + 1X PNA
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Figure 35: A. 12% TBM gel with 15µM samples preincubated with 5mM magnesium at 21°C.
Lane 1- 5BSL3.2, Lane 2-X55, Lane 3-5BSL3.2+X55, Lane 4 to7-X55+5BSL3.2+PNA (2 hour),
Lane 8 to11 5BSL3.2+X55+PNA (1 hour)
B. 12% TBM gel with 5mM magnesium at 37°C. Lane 1- 5BSL3.2, Lane 2-X55, Lane 3-5BSL3.2+X55,
Lane 4 to7-X55+5BSL3.2+PNA (2 hour), Lane 8 to11 5BSL3.2+X55+PNA (1 hour)
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Finally, we added an 8-fold excess of PNA to preformed kissing complex samples
of 5BSL3.2-X55 and analyzed it at different time intervals. The purpose of this
experiment was to examine at excess PNA concentration and higher time intervals,
whether the PNA loses specificity or if it exhibits different interactions with X55. As
shown in figure 36, lanes 4-7, at 37°C within an incubation time of 1 hour, with 8 fold
PNA, both the homodimer and heterodimer interactions of X55 RNA are disrupted (as
observed earlier). Furthermore, the intensity of bands from lane 4-7 appears constant,
thereby suggesting that even at 8-fold excess and up to incubation period of 4 hours, PNA

5BSL3.2 + X55 (4hr)

5BSL3.2 + X55 (3hr)

5BSL3.2 + X55 (2hr)

5BSL3.2 + X55

X55

5BSL3.2
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Band C
X55 Homodimer
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3

4
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6

7

Figure 36: 12% TBM gel with 5mM magnesium. 15µM samples were pretreated with magnesium. Lane 1X55, Lane 2-5BSL3.2, Lane 3-5BSL3.2+X55, Lane 4 to7-X55+5BSL3.2+8-fold PNA for 1-4 hour
at 37°C)

5.2 Conclusion-PNA a possible therapeutic agent
Based on these results we can definitely confirm that the γ substituted PNA
designed by us and synthesized by the Ly group in this study is highly specific to its
target X55 RNA at concentrations up to 8 fold of target RNA. The efficiency of PNA
appears to be similar at both 21°C and 37°C, with as little as 1-fold PNA being efficient
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in completely disrupting both the homo- and hetero-interactions of X55 in a time period
of an hour. In addition, even at lower than 1 fold concentrations, the PNA affected the
homo and hetero interactions of X55. Thus, the single PNA designed in this study,
possesses this dual ability to disengage two different interactions of X55. Though the
biological significance of X55 dimerization remains to be elucidated, the 5BSL3.2-X55
interaction has been demonstrated to be essential for replication. Thus at least one of the
known biologically significant interactions of X55 RNA is disrupted by the PNA
designed in this study. Furthermore, even assuming that the HCV genomic dimerization
is not of biological importance, the ability of PNA to stabilize the X55 monomer and
homodimer might make it functionally unavailable for other essential interactions within
the HCV genome.
Moreover, the HCV IRES, against which all PNA to date has been investigated,
has highly conserved sequences, but only a few short (~5-7 nts) motifs are 100%
conserved among the different HCV genotypes (56,57). The issue with such small motifs
being used as targets is that these motifs may have homology within the human hepatic
cell thereby leading to nonspecific and undesired interference. To solve the problem of
nonspecific interaction, if suppose PNA is synthesized such that the target sequence is
extended on both sides of these short 100% conserved motifs then due to the mutational
character of HCV, the chances of PNA and target RNA mismatch is very high on both
the ends of the 100% conserved short motifs. It has already been shown by the Ly group
that a single mismatch between PNA-RNA pair reduces the Tm of the duplex by 11-18°C
and thus mismatches could prove deleterious (94).
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X55 RNA on the other hand is a 55 nt long 100% conserved sequence within
HCV and has already been demonstrated (44) to have no cellular homology, and thus if
used as an target it further reduces any chance of nonspecific interaction. All of this
strongly suggests that the new γ substituted PNA is promising as a strong therapeutic
agent and X55 (100% conserved among all genotypes) as an important therapeutic target.
Another option for HCV cure would be combination therapy. This type of therapy
is now commonly being used against the highly mutational HIV. So in analogy, for
treatment of HCV, in combination with PNA against long 100% conserved sequences of
HCV, even the short 100% motifs in the 5’UTR and coding region of HCV should be
simultaneously targeted. This approach would probably have a stronger impact rather
than single targets within HCV.
Another important concern with PNA being a therapeutic tool is that HCV has a
non-structural protein- NS3, which functions as both a protease and a helicase. Helicases
are enzymes that function as motor proteins and move either 5’→3’ or 3’→5’along the
phosphodiester backbone of annealed nucleic acid strands and unwind them, while
mostly using energy from ATP hydrolysis (102,103). This unwinding of annealed strands
is crucial for important life processes such as replication, repair, recombination and
others (104-107 and references therein). NS3 is reported as a 3’→5’helicase that uses a
passive mechanism for unwinding which means that it doesn’t not bind to both the duplex
strands, but instead it binds to that strand of the duplex which would have a single
stranded sequence on either end of the duplex (103). Given this function of NS3 it would
be not only interesting but also important for therapeutic purposes to investigate the
effect of NS3 as helicase on the new γ substituted PNA-X55 duplex. A study in 2001 by
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Raney group showed that NS3 a 3’→5’helicase finds PNA-RNA heteroduplex an
unfavorable substrate (103). In their study they used short RNA and DNA duplexes as
well as short PNA strands. Thus although the current study indicates γ substituted PNA
as a beneficial tool, further studies analyzing NS3 interference is required along with
examining in vivo efficiency of the γ substituted PNA.
Most potential anti HCV compounds are currently in the last stages of
development. However given the highly mutational character of HCV, it will not be long
before drug resistant HCV species originate. Thus targeting significantly long genomic
sequences of HCV that are extremely crucial for the virus would be the best strategy for
cure. In this study we investigated a uniquely modified PNA synthesized by the Ly group
for its potential in vitro against a 55 nt long sequence that is 100% conserved among
HCV genotypes. However, for future it would be necessary to examine the efficacy of γ
substituted PNA in vivo.
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Chapter 6: SUMMARY
More than two decades, since its discovery, the highly mutational Hepatitis C
virus (HCV), like HIV, currently has no complete therapeutic options and the existing
therapy pose the problem of intolerance. Given the high global population (3%) currently
infected with HCV and its highly mutational nature, characterization of any essential
sequence within the HCV particle could have huge impact in developing therapeutic
options.
In this study we investigated, four different 100% conserved sequences within X
RNA, 5BSL3.2, IIId and Alt regions of the HCV RNA genome that can be potential
targets for therapy. We show these 100% HCV RNA sequences to be involved in varied
interactions with each other via a common mechanism of kissing complex. Two of these
interactions have already been demonstrated to be essential for replication. Thus
characterization of these interactions provides valuable information on HCV that can be
exploited for developing a cure. Moreover, our results on these interactions have allowed
us to envision a possible model for the sequence of interactions occurring within HCV
life cycle, which even today is ambiguous. Also, we have successfully designed a single
PNA that can disrupt more than one interaction of X55, thereby opening new potential
therapeutic options. However, further evaluation of the PNA as a therapeutic tool in vivo
needs to be validated. Also, analysis of PNA against the other conserved sequences,
could aid in development of effective combination therapy (as in HIV).
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